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Abstract 
Expression of functional breast cancer susceptibility gene 1 (BRCA1) in human cancers is 
associated with resistance to platinum-based chemotherapeutics and poly(ADP-ribose) 
polymerase (PARP) inhibitors.  BRCA1 is a nuclear phosphoprotein with broad tumor 
suppressor activities that, among other functions, is critical for resolving double-strand DNA 
breaks (DSBs) and interstrand crosslinks (ICLs) by homologous recombination (HR).  In vitro, 
animal and human clinical data have demonstrated that BRCA1-deficient cancers are highly 
sensitive to ICL-inducing alkylative chemotherapeutic agents, are amenable to synthetic lethal 
approaches which exploit defects in DSB/ICL repair (e.g., PARP inhibitors), and are generally 
associated with more favorable responses to anti-neoplastic therapy and improved survival.  
Conversely, high expression of wild-type BRCA1 in a number of cancers, as well as frame-
restoring intragenic mutations in BRCA1 mutant ovarian cancers, is associated with therapeutic 
resistance and poor prognosis.  Accordingly, there has been much interest in identifying, 
exploiting and manipulating DSB/ICL repair capacity to restore or enhance sensitivity to cancer 
therapeutics.  In this study, we demonstrate that the heat shock protein 90 (HSP90) inhibitor 17-
allylamino-17-demethoxygeldanamycin (17-AAG (Tanespimycin)), which is currently in Phase 
II/III clinical evaluation, induces BRCA1 ubiquitination and proteasomal degradation in 
numerous in vitro models.  Mechanistically, we show that loss of HSP90 function completely 
abolishes both homologous recombination and non-homologous end joining of DSBs, that 
BRCA1-deficient cells are hypersensitive to 17-AAG due to enhanced replication stress and 
aberrant entry into mitosis, and that 17-AAG can reverse BRCA1-dependent repair-mediated 
resistance.  Additionally, we assessed the role of BRCA1 promoter methylation in sporadic triple-
negative breast cancers (TNBCs) and identify a novel biomarker for poor response to 
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anthracycline regimens in human patients.  In summary, we document a novel upstream HSP90-
dependent regulatory point in the Fanconi anemia/BRCA DSB/ICL repair pathway, illuminate 
the role of BRCA1 in regulating damage-associated checkpoint and replication responses to 
HSP90 inhibitors, specifically identify BRCA1 as a novel, clinically relevant target for 
enhancing radio- and chemosensitivity in refractory and/or resistant malignancies, and identify a 
useful biomarker for studies of therapeutic sensitivity in human TNBCs. 
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Chapter I:  Introduction 
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Introduction 
Inherited defects in DNA repair pathways underlie numerous cancer susceptibility syndromes.  
Acquired defects in these same pathways are commonly seen in sporadic cancers and are 
responsible for the genomic instability that is a universal hallmark of cancer.  Fanconi anemia 
(FA) and hereditary breast and/or ovarian cancer (HBOC) are two inherited syndromes whose 
pathogeneses stem from defects in DNA repair.  At the molecular level, these disorders are 
fundamentally related as products of the Fanconi anemia (FANC) and breast cancer 
susceptibility (BRCA) genes operate in concert to repair specific types of DNA damage—
indeed, BRCA2 and FANCD1 are the same gene.  Though HBOC is responsible for a minority of 
all breast and ovarian cancers and FA is an exceedingly rare disease (1-5 cases per one 1 million 
persons) (D'Andrea, 2010), acquired defects or deficiencies in the FA/BRCA pathway are 
relatively common and may have profound implications for therapeutic efficacy in sporadic 
cancers. 
 
Fanconi Anemia 
FA is a rare recessive disorder with tremendous locus heterogeneity.  Fifteen complementation 
groups are currently recognized and, with the exception of the FANCB complementation group, 
all are inherited in an autosomal recessive fashion (Table 1) (Wang, 2007).  This disease is 
disproportionately seen in Ashkenazi Jewish individuals and several unique mutations in 
complementation groups FANCC, FANCA and BRCA2/FANCD1 are seen in this population 
(Kutler and Auerbach, 2004). Congenital anomalies are diverse in FA, with short stature, 
developmental disability, and physical defects of the skin, limbs, head, eyes, ears, and kidneys 
being most common.  The most troublesome early manifestation of FA is bone marrow failure, 
2
Complementation 
Group
Gene Alias(s) Mapping
Percentage of 
FA Patients
FANCA FANCH 16q24.3 62.3
FANCB FAAP95 Xp22.2 2.1
FANCC 9q22.32 13.7
FANCD1 BRCA2 13q12.3 2.5
FANCD2 3p25.3 0.2
FANCE 6p21.31 2.6
FANCF 11p14.3 1.7
FANCG XRCC9 9p13.3 9.5
FANCI KIAA1794 15q26.1 1.4
FANCJ BRIP1 , BACH1 17q23.2 2.0
FANCL PHF9, FAAP43 2p16.1 0.2
FANCM 17q21.2 0.2
FANCN PALB2 16p12.2 0.7
FANCO RAD51C 17q22 0.5
FANCP SLX4 16p13.3 0.5
3
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which typically develops during the first decade of life (Alter et al., 2003).  Additionally, 20% or 
more of FA patients develop cancer.  Though individuals with FA are at increased risk for an 
array of malignancies, acute myelogenous leukemia is the most common (Kutler et al., 2003).  
Androgens and hematopoietic growth factors may ameliorate or delay bone marrow failure, 
though allogeneic stem cell transplantation from a suitable donor is often necessary and remains 
the only curative treatment for incipient bone marrow failure.  Because of inherent 
hypersensitivity to DNA damaging agents, FA patients require a modified bone marrow 
transplant procedure, employing low-dose chemotherapy and limited field irradiation (Gluckman 
et al., 1995; Gluckman and Wagner, 2008).  Even in cases where a matched donor is found and 
engraftment is successful, the patient remains at heightened risk for a number of solid tumors.  
Readers are referred to a recent review by D’Andrea (D'Andrea, 2010) or Online Mendelian 
Inheritance in Man (OMIM) entry #227650 for a comprehensive review of the clinical and 
genetic features of FA. 
 
Hereditary Breast and/or Ovarian Cancer 
Inherited mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 are responsible 
for approximately 50% of all hereditary breast cancers and 45% of all hereditary ovarian cancers.  
Estimates of penetrance of BRCA1 and BRCA2 germline mutations vary significantly in different 
series, but a meta-analysis of 22 population-based studies examining 8,139 index cases, 500 of 
whom were found to carry a germline mutation in BRCA1 or BRCA2 has given valuable average 
estimates of cancer risk in mutation carriers (Antoniou et al., 2003).  The cumulative risk of 
BRCA1 mutation carriers developing breast or ovarian cancer by age 70 was found to be 65% 
(44-78%) and 39% (18-54%), respectively.  Inheritance of a single defective BRCA2 allele was 
5
 
found to be associated with a 45% (31-56%) and 6% lifetime risk of breast cancer in females and 
males, respectively, 11% (2.4-19%) lifetime risk of ovarian cancer, and a significantly increased 
risk of cancers of the prostate, pancreas, larynx, stomach and skin melanocytes (1999; Antoniou 
et al., 2003).  As described previously, individuals with inherited biallelic defects in the BRCA2 
gene develop FA, as BRCA2 and FANCD1 are the same gene.  Similarly, while germline biallelic 
defects in the FANCN/PALB2 and FANCJ/BRIP1 genes cause FA, inherited monoallelic defects 
in these same genes account for 2% of non-BRCA1/2 HBOC families (Rahman et al., 2007; Seal 
et al., 2006).  As in Fanconi anemia, deleterious mutations in the BRCA1 and BRCA2 genes are 
more common in individuals of Ashkenazi Jewish descent.  Indeed, approximately 2.5% of 
Ashkenazi Jews unselected for family history of breast cancer will carry a founder mutation in 
BRCA1 (185delAG or 5382insC) or BRCA2 (6174delT).  These three mutations account for 78-
96% of all BRCA1 or BRCA2 mutations seen in this population (Rubinstein, 2004).  A follow-up 
study from the previously mentioned meta-analysis examined breast and ovarian cancer risks 
specifically in individuals carrying one of the three Ashkenazi founder mutations and found that 
generally, cancer risks associated with these three mutations were similar to risks of non-
Ashkenazi founder BRCA1 or BRCA2 mutations, though the 6174delT BRCA2 mutation 
conferred a higher than expected ovarian cancer risk (Antoniou et al., 2005). 
 
The FA/BRCA Pathway 
Positional cloning, biochemical analysis and functional complementation studies in families with 
FA and with HBOC enabled the identification of the genes that now define the 15 
complementation groups associated with FA and the two distinct genetic variants of HBOC. One 
of the hallmarks of FA is cellular sensitivity to DNA crosslinking agents like diepoxybutane 
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(DEB) or mitomycin C (MMC).  Indeed, measurement of chromosomal breaks in primary 
lymphocytes following exposure to DEB exposure remains a mainstay of FA diagnosis 
(Auerbach and Wolman, 1976).  Because of common clinical findings and hypersensitivity to 
DEB regardless of complementation group, the products of these genes all presumably operate in 
a single pathway.  It is now known that eight of the 15 FA genes (FANCA, B, C, E, F, G, L and 
M) assemble a core nuclear ubiquitin ligase complex that regulates the activity of two other FA 
proteins, FANCD2 and FANCI.  Upon recognition of an interstrand crosslink (ICL), FANCM, 
Fanconi anemia-associated protein 24 (FAAP24) and FANCM-associated histone fold 1/2 
(MHF) bind near the ICL and recruit the eight-membered core complex.  This assembly then 
monoubiquitinates FANCD2 and FANCI (Figure 1, Steps 1-2).  These modified proteins 
associate with chromatin and recruit Fanconi anemia-associated nuclease (FAN1), which 
cooperates with other proteins to excise the ICL, induce a double-strand break (DSB) and prime 
the broken DNA strands for repair (Figure 1, Steps 2-5).  After FAN1-mediated excision to form 
free 3’ flaps of single-strand DNA (ssDNA) (Figure 1, Step 6), the FANCN, FANCJ, BRCA1 
and BRCA2 proteins assemble and nucleate the ssDNA with RAD51 (Figure 1, Step 7).  This 
enables invasion of the remaining broken strand and repair by homologous recombination (HR) 
(Figure 1, Step 8).  The products of the FA and BRCA genes are all required for efficient and 
high-fidelity repair of ICLs.   
 
Not surprisingly, mutation of or deficiency in any of these genes would be expected to abrogate 
ICL repair and result in hypersensitivity to crosslinking agents.  Several traditional cytotoxic 
agents used in chemotherapy induce ICLs, including cisplatin (and derivatives), nitrosoureas 
(e.g., carmustine), nitrogen mustards (e.g., cyclophosphamide and melphalan) as well as the  
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antitumor antibiotic mitomycin C.  Tumors with defects in the FA/BRCA pathway commonly 
respond more favorably to these agents than do tumors with an intact FA/BRCA pathway.  Thus, 
while inherited mutations in the FA and BRCA genes incite genomic instability and predispose 
to tumorigenesis, defects in these genes may also be an Achilles’ heel.  By identifying 
impairments in the FA/BRCA pathway, it may be possible to tailor cytotoxic chemotherapy to 
exploit intrinsic vulnerabilities within the DNA repair machinery.  Ideally, this approach will 
lead to better responses to traditional chemotherapeutic regimens and will spare patients the 
exposure to and side effects of inappropriate chemotherapy.  Even more recently, therapeutic 
strategies based on synthetic lethality have emerged that demonstrate remarkable selectivity for 
cells with inherited or acquired defects in homologous recombination. 
 
The remainder of this chapter will (1) discuss the relevance of synthetic lethal approaches to 
tumors with defects in homologous recombination, (2) detail studies which have identified 
cancer-associated alterations in the FA/BRCA pathway and linked such changes to altered 
responses to specific chemotherapeutic agents, and (3) review novel approaches to identify, 
quantitate and manipulate FA/BRCA function in human tumors. 
 
Synthetic Lethality 
Targeted anti-neoplastic therapy is the long sought after Holy Grail of cancer medicine.  Though 
we have identified, developed and instituted only a small handful of such agents into oncology, 
the unprecedented improvements we have observed in diseases like chronic myelogous leukemia 
have fueled our endeavors to engineer the next generation of miracle drugs.  While the bulk of 
this chapter will discuss genetic and epigenetic variations in DNA repair that induce 
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hypersensitivity to traditional cytotoxic chemotherapeutic drugs, many breast and most ovarian 
cancer patients still experience therapeutic failure at some point during the course of their 
disease, illuminating the need to further elucidate the genetic and evolutionary principles at the 
interface between cancer cell biology and therapy.  Towards this end, a recent advance based on 
synthetic lethality, a genetic principle first described 90 years ago (Bridges, 1922) shows 
promise in selectively targeting cancer cells that arise in patients with inherited BRCA1 and 
BRCA2 mutations. 
 
The concept 
Synthetic lethality is a genetic state in which simultaneous inactivation of two genes (or 
pathways) is lethal, while loss of one or the other alone is viable.  The therapeutic potential of 
this principle in oncology was first recognized and demonstrated in cancers arising in BRCA1 
and BRCA2 mutation carriers.  Normal cells in BRCA1 or BRCA2 mutation carriers are proficient 
in DSB repair because one functional allele is sufficient.  The breast, ovarian and other 
malignancies that arise in such individuals follow loss of heterozygosity (LOH) of the remaining 
normal BRCA1 or BRCA2 allele.  Thus, only the neoplastic cells that have sustained LOH are 
defective in DSB repair, and this almost certainly explains the hypersensitivity of BRCA1/2-
associated breast and ovarian cancers to DNA damaging agents (Cass et al., 2003; Chappuis et 
al., 2002).  While the loss of BRCA1/2 function instigates tumorigenesis in HBOC patients, the 
unique genetic state present in their cancer cells lends to therapeutic exploitation.  Pioneering 
studies by Ashworth identified that BRCA1 or BRCA2 dysfunction profoundly sensitized cells 
to inhibitors of poly(ADP)ribose polymerase (PARP), an enzyme involved in base excisional 
repair (BER) of DNA (Farmer et al., 2005).  The underlying reason for this hypersensitivity was 
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said to be that in the absence of PARP activity, there is persistence of DNA lesions that are 
normally repaired by homologous recombination.  Inhibition of PARP induces synthetic lethality 
selectively in cells which have sustained LOH at the BRCA1 or BRCA2 loci because non-
neoplastic (i.e., BRCA1 or BRCA2) heterozygous cells retain HR competence and can thus 
survive loss of BER capacity (Figure 2).   Subsequent studies by Ashworth revealed that 
deficiency of a number of proteins involved in HR, including RAD51, NBS1, ATR, ATM, 
CHK1, CHK2, FANCD2, FANCA, and FANCC all induced hypersensitivity to PARP 
inhibition, implying that the hypersensitivity phenotype is indeed due to failure of HR-mediated 
repair and that PARP inhibition may not only be a viable therapeutic option for BRCA1/2-
mutation associated cancers, but rather a wide range of tumors with defects in the HR pathway 
(McCabe et al., 2006). 
 
PARP inhibitors in BRCA1/2-mutation associated malignancies 
Several PARP inhibitors have been developed and are now in clinical evaluation.  Among the 
earliest of these agents was AZD-2281 (olaparib), a potent orally bioavailable PARP inhibitor 
that was evaluated in a cohort of 60 patients, 22 of whom were carriers of BRCA1 or BRCA2 
mutations with breast, ovarian or prostate cancers who had previously received multiple 
treatment regimens.  This study reported few adverse effects and 63% of the mutation carriers 
had objective radiologic or biochemical evidence of tumor response or significant periods of 
disease stabilization.  Importantly, none of the non-mutation carriers demonstrated any objective 
antitumor activity with AZD-2281 treatment, supporting the notion that PARP and the BRCA1/2 
pathway are related in a synthetic lethal manner (Fong et al., 2009).  A similar conclusion was 
reached in another study of 50 ovarian cancer patients, 48 of whom had germline BRCA1 or 
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BRCA2 mutations, with an overall clinical benefit rate of 46% with olaparib (Fong et al., 2010).  
Two additional studies enrolling only BRCA1/2-mutation-associated advanced breast cancer and 
recurrent ovarian cancer demonstrated objective response rates of 41% and 33%, respectively, 
and clinical benefit rates of 52% in both studies for patients on the higher dose of olaparib 
(Audeh et al., 2010; Tutt et al., 2010).  Another recent study by O’Shaughnessy and colleagues 
evaluated the efficacy of gemcitabine and carboplatin, with or without iniparib, (BSI-201, 
Sanofi-aventis), another small-molecule proposed to inhibit PARP, in 123 patients with 
metastatic triple-negative breast cancer.  This study did not classify patients based on BRCA1/2 
mutation, but evaluated clinical benefit, overall rate of response, progression-free survival and 
overall survival.  In the intention-to-treat population, the addition of iniparib to chemotherapy 
increased clinical benefit from 34% to 56%, overall response rate from 32% to 52%, progression 
free survival from 3.6 to 5.9 months, and overall survival from 7.7 to 12.3 months 
(O'Shaughnessy et al., 2011).  Despite this promising phase 2 trial of iniparib, a phase 3 trial 
failed to prolong survival in triple-negative breast cancer patients.  Two major problems exist in 
these studies; the first being that the phase 2 trial by O’Shaughnessy (O'Shaughnessy et al., 
2011) did not evaluate BRCA1/2 mutation status or dysfunction, and was thus unable to ascertain 
whether therapeutic benefit in triple negative lesions was disproportionally skewed towards 
benefiting BRCA mutation carriers.  Secondly, the exact mechanism of action for iniparib 
remains unknown, and a very recent study provides compelling evidence that the drug non-
selectively modifies cysteine-containing proteins and is thus not a bona fide PARP inhibitor (Liu 
et al., 2012).  Shortly after the announcement of the phase 3 iniparib failure, AstraZeneca 
announced that it would not be pursuing phase 3 development of olaparib for BRCA1/2-
associated breast cancer.  The latter decision has caused substantial concern and dismay among 
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many scientists, physicians and breast cancer patients alike, as many believe there is substantial 
evidence to support use of olaparib in BRCA1/2-associated breast cancer (Guha, 2011).  Though 
the spirited excitement that initially surrounded PARP inhibitors has been replaced by a more 
cautious enthusiasm, many remain optimistic that this class of agents will find use in breast, 
ovarian and other malignancies.  Above all, the perceived failure of PARP inhibitors in breast 
cancer testifies to the heterogeneity of this disease.  Additional biomarker studies and clinical 
trials which account for BRCA status and other parameters of HR capacity will likely identify 
subsets of patients who will benefit from these agents. 
 
PARP inhibitors in sporadic malignancies 
A study by Hennessy, et. al. evaluated BRCA1 and BRCA2 gene integrity and mRNA expression 
in 235 unselected ovarian cancers and noted that 19% of the tumors in this cohort had a mutation 
in either BRCA1 or BRCA2.  Among the patients with tumor BRCA1/2 mutations who had 
provided both tumor and germline DNA for analysis (n = 28), it could be demonstrated that 
somatic (i.e., acquired) mutation of BRCA1 and BRCA2 accounted for 43% and 29% of all 
mutations identified, respectively.  This study estimated that approximately 7% of all sporadic 
ovarian cancers have sustained a somatic mutation in either BRCA1 or BRCA2.  As will be 
discussed below, this study concurs with others demonstrating that loss of BRCA1/2 function is 
associated with improved progression-free survival after platinum-based chemotherapy 
(Hennessy et al., 2010).  Though PARP inhibitor therapy was not used in this study, when 
considering inherited and somatic mutations in BRCA1/2, downregulation of BRCA1/2 mRNA 
or protein, or possessing a “BRCAness” gene expression signature, up to 42% of ovarian cancer 
patients may benefit from PARP inhibitors (Hennessy et al., 2010; Konstantinopoulos et al., 
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2010; Quinn et al., 2007; Swisher et al., 2009; Teodoridis et al., 2005; Weberpals et al., 2009).  It 
is possible that patients with other sporadic malignancies that exhibit defects in the FA/BRCA 
pathway will enjoy clinical benefit from PARP inhibitors, highlighting the importance of both 
identifying classes of cancers with such defects, as well as defining diagnostic tools to identify 
individual patients that will benefit from these therapies. 
 
Though inhibition of base excision repair in cancers with impaired homologous recombination is 
the first example of synthetic lethality that has been successfully implemented into clinical 
oncology, malignant cells are richly endowed with unique genetic and epigenetic alterations that 
may lend to such approaches.  Another study by Ashworth and colleagues reported a synthetic 
lethal relationship between dysfunction of the mismatch repair (MMR) pathway and the 
dihydrofolatereductase inhibitor methotrexate.  Inherited mutations in MMR pathway genes, 
most commonly MSH2 and MLH1, lead to hereditary non-polyposis colorectal cancer (HNPCC, 
also known as Lynch syndrome) and dramatically increase risk for ovarian, endometrial, gastric 
colorectal and other malignancies.  Ashworth demonstrated that treatment with methotrexate led 
to accumulation of oxidized bases in MSH2-deficient cells, but not in cells with an intact MMR 
pathway (Martin et al., 2009).  This finding has led to a phase II trial of methotrexate in MSH2-
deficient metastatic colorectal cancer. 
 
Studies which identify additional synthetic lethal relationships between specific recurrent 
molecular abnormalities in human cancers and “druggable” targets are sorely needed and would 
offer great promise in clinical oncology. 
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FA/BRCA Dysfunction in Human Cancers and Association with Therapeutic Sensitivity 
Though Fanconi anemia is a rare recessive disorder and hereditary breast and/or ovarian cancer 
accounts for a minority of all breast and ovarian malignancies, polymorphisms with functional 
significance, somatic mutations, and epigenetic silencing of the BRCA and/or FA genes are 
relatively common in diverse human cancers.  Numerous studies have correlated these genetic 
and epigenetic signatures with clinicopathological features of malignancy, response to 
chemotherapeutic agents, and with prognosis and survival (Table 2). 
 
Breast Cancer 
BRCA1, BRCA2 and the Intrinsic Molecular Subtypes of Human Breast Cancer 
Breast cancer is a heterogeneous disease at both the histological and molecular level.  Gene 
expression profiling of large cohorts of human breast cancers has established five major intrinsic 
subtypes of invasive breast cancer:  luminal type A, luminal type B, basal-like, HER2
+
, and 
normal breast-like (Sorlie et al., 2001).  Retrospective analysis of patient outcomes in these 
studies demonstrated that specific molecular taxonomies are strongly correlated with unfavorable 
clinical behavior and poor overall survival.  Specifically, the basal-like and HER2-
overexpressing tumors are associated with an aggressive clinical course, resistance to 
chemotherapy, and increased risk of distant metastasis (Rodriguez-Pinilla et al., 2006; Sorlie et 
al., 2001; Sorlie et al., 2003).  The basal-like breast cancers (BLBCs) were so named because 
these neoplasms consistently express molecules normally confined to the basal/myoepithelial 
compartment of the ductal and lobular epithelium.  BLBCs account for approximately 15% of all 
invasive breast cancers and are typically of high histological grade, demonstrate high mitotic 
indices, mutations in the TP53 tumor suppressor gene, and almost uniformly lack expression of 
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estrogen receptor (ER), progesterone receptor (PgR), and HER2 (Turner and Reis-Filho, 2006; 
Turner et al., 2007).  Due to the absence of these receptors, BLBCs are not amenable to the 
targeted anti-estrogen and anti-HER2 therapies that have drastically improved survival of 
patients diagnosed with luminal-type or HER2-overexpressing tumors.  Traditional cytotoxic 
chemotherapy is the only approved available systemic treatment for BLBCs.  Accordingly, 
among all molecular classifications of breast cancer, the basal-like malignancies are associated 
with the most aggressive clinical behavior and poorest prognosis (Sorlie et al., 2001). 
 
An intimate correlation has been recognized between the basal-like phenotype and deficiency of 
BRCA1.  Transcriptional profiling of large cohorts of BRCA1-mutated breast cancers has 
revealed that these tumors generally cluster in the basal-like subtype (Foulkes et al., 2003; 
Lakhani et al., 2005; Sorlie et al., 2003).  Moreover, immunohistochemistry studies reveal that 
nearly 70% of BRCA1-mutated breast cancers express basal cytokeratins and lack expression of 
ER, whereas this immunophenotype is present in less than 9% of matched control tumors 
(Lakhani et al., 2005).  Sporadic malignancies in which BRCA1 has been transcriptionally or 
epigentically silenced also have a strong tendency to be of the basal-like phenotype (Thompson 
et al., 1995; Turner et al., 2007).  Conversely, tumors which maintain expression of functional 
BRCA1 are almost uniformly luminal type cancers and are accordingly associated with more 
indolent clinical courses, responsiveness to endocrine therapies, and improved survival (Catteau 
et al., 1999; Yang et al., 2001).  Taken together, these findings suggest that loss of BRCA1 
expression and/or function has a causal role in the development of the basal-like phenotype.  
Though this association is now well-supported, the molecular consequences of BRCA1 
deficiency that result in the generation of BLBCs remain undefined. 
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Recent studies support a model in which BRCA1 is necessary for the normal luminal 
differentiation program within the mammary gland.  In vitro and in vivo studies have revealed 
that loss of BRCA1 expression in mammary epithelial cells leads to marked dysplasia and failure 
of terminal luminal epithelial cell differentiation (Furuta et al., 2005; Lim et al., 2009; Liu et al., 
2008).  These morphological abnormalities are associated with exaggerated expression of 
basal/myoepithelial antigens and enrichment of cells with expression of the putative 
stem/progenitor cell marker ALDH1A1 (Lim et al., 2009; Liu et al., 2008; Xu et al., 1999).  
While these findings would suggest that BRCA1 deficiency may cause BLBCs by causing 
expansion of the basal/myoepithelial population, a recent study has documented profound 
expansion of the CD49f
+
/EpCAM
+
 luminal progenitor population in the pre-malignant breast 
tissue of BRCA1-mutation carriers.  The same study revealed that the luminal progenitor 
population, and not the basal/myoepithelial population, more closely resembles the 
transcriptional profile of BLBCs (Lim et al., 2009).  Since BRCA1 deficiency is known to result 
in genetic instability, cell cycle abnormalities, and aberrant centrosome duplication (Deng, 
2006), it is plausible to assert that BRCA1 deficiency results in stalled terminal differentiation of 
luminal progenitor cells that are genetically unstable and are destined to produce aggressive 
basal-like malignancies. 
 
Inherited mutations in BRCA1 or BRCA2/FANCD1 account for only 5-10% of all breast cancers.  
The remaining 90-95% are sporadic in nature, and demonstrate tremendous molecular and 
morphological diversity.  Immunohistochemically, breast cancers are classified into three major 
groups depending on expression of ER, PR and HER2.  Approximately 60% of all breast cancers 
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express ER and/or PR and are amenable, to varying degrees, to endocrine therapies that are 
aimed at regulating estrogen production or signaling through the estrogen receptor.  The second 
class, accounting for roughly 25% of all breast cancers, are those that have amplified HER2 
expression, but generally lack ER and PR expression.  These lesions are more aggressive than 
those without HER2, but agents like trastuzumab (Herceptin®) and lapatinib (Tykerb®) have 
dramatically improved clinical outcomes in HER2+ breast cancer.  The third class, the so called 
“triple-negative” (TN) malignancies lack expression of ER, PR and HER2.  These tumors are 
sensitive to neither endocrine therapies nor HER2-targeted therapies and exhibit aggressive 
biological features.  Approximately 15% of all invasive breast cancers are of the TN subtype, 
though these tumors are overrepresented in patients with metastatic disease and account for a 
discordantly high proportion of breast cancer-related deaths.  The aggressive biological 
properties of TN breast cancers coupled with a paucity of approved targeted therapeutic agents 
makes TN breast cancer an enduring clinical obstacle.  Fortunately, and of direct relevance to 
this dissertation, TN cancers of both sporadic and hereditary (i.e., BRCA1/2-related) origin 
appear to have recurrent defects in double-strand break (DSB) repair, due largely to genetic or 
epigenetic perturbations of the BRCA1 gene (Turner et al., 2007).  Chemotherapeutic approaches 
aimed at exploiting such defects are being intensely evaluated and may dramatically improve 
clinical outcomes for TN breast cancer patients. 
 
Because of the unique natural history of BRCA1/2-associated breast cancer, several groups 
sought to assess whether recurrence and/or survival differed between BRCA-associated and 
sporadic cancers.  Many of these early studies reported conflicting data, with several noting no 
significant difference in clinical course (Gaffney et al., 1998; Johannsson et al., 1998; Robson et 
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al., 1998; Verhoog et al., 1998), and others reporting adverse outcomes in BRCA1 or BRCA2 
mutation carriers (Ansquer et al., 1998; Chappuis et al., 2000; Stoppa-Lyonnet et al., 2000).  
These studies potentially conflict with another early study by Chappuis, et. al., who 
demonstrated a more favorable objective response to DNA damaging chemotherapy in 
BRCA1/2-associated breast cancers than in sporadic tumors, in which 91% of breast cancers in 
BRCA1/2 mutation carriers demonstrated clinical complete response (cCR) and 44% pathological 
complete response (pCR) compared to only a 30% cCR and 4% pCR in non-carriers after three 
or four cycles of anthracycline-based neoadjuvant chemotherapy (Chappuis et al., 2002).  The 
higher response rate observed in carriers was presumed to be due to impaired DNA repair 
mechanisms and hypersensitivity to chemotherapy in those cancers with BRCA pathway defects.  
This group was one that had immediately prior to this study demonstrated that BRCA1/2-
associated breast cancer was associated with a worse prognosis (Chappuis et al., 2000).  Using 
data from yet another study of 292 Ashkenazi Jewish breast cancer patients, they offered an 
explanation for this apparent paradox, as it was observed that overall survival in BRCA1-
associated cancers was poorer only in women who did not receive adjuvant chemotherapy, 
positing that the less favorable outcome observed in some retrospective studies may be 
explained, at least in part, by the omission of chemotherapy in these historical series (Chappuis 
et al., 2011).  Bordeleau et al., recently published a highly informative critical analysis of early 
and contemporary studies addressing the prognosis of BRCA1/2-associated breast cancers.  In 
addition to addressing methodological and statistical limitations of many of these studies, the 
major conclusion of this analysis is that prognosis of BRCA-associated breast cancer appears to 
be similar to that observed in sporadic breast cancer (Bordeleau et al., 2010).  It is important to 
note that in many of these studies, BRCA1- and BRCA2-associated breast cancers were analyzed 
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together, despite the obvious histological and molecular differences between these groups.  The 
BRCA2-associated breast cancers appear in most respects to resemble the more common 
hormone receptor-positive cancers that comprise the bulk of sporadic lesions, while the 
pathogenesis of BRCA1-associated tumors is quite distinct and, as noted previously, leads in 
most cases to triple-negative breast cancer.  It is possible that alternate trends may have emerged 
in some of these studies had the BRCA1- and BRCA2-associated tumors been treated as 
biologically distinct entities instead of a unified group of familial cancers. 
 
Given the heterogeneous nature of sporadic breast cancer, many recent studies have sought to 
directly examine the integrity and/or functionality of various components of the FA/BRCA 
pathway as potential biomarkers of therapeutic efficacy.  To study the DNA damage response 
immediately following neoadjuvant chemotherapy, Asakawa and colleagues collected core 
needle biopsies before and 18-24 hours after the first cycle of epirubicin plus cyclophosphamide 
(EC) and examined cellular localization of DNA damage repair proteins, including BRCA1, 
γH2AX and RAD51 (Asakawa et al., 2010).  This study noted that tumors with low baseline 
staining for BRCA1 nuclear foci exhibited a greater reduction in tumor volume than those with 
high BRCA1 staining following EC therapy.  Moreover, this study devised a simple DNA 
damage response (DDR) scoring system which took into account baseline (i.e., pre-therapy) 
γH2AX, BRCA1 and RAD51 foci formation as well as post-EC RAD51 staining and noted that 
DDR score was inversely correlated with tumor volume reduction after EC, and was more 
informative than either nodal status or primary tumor size in predicting response (Asakawa et al., 
2010).  Unlike other tumor suppressors involved in the pathogenesis of breast cancer, somatic 
mutational inactivation of BRCA1 is an exceedingly rare event.  Our group was the first to 
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demonstrate that downregulation of BRCA1 was a relatively common event in sporadic breast 
cancer progression (Thompson et al., 1995).  Many studies have since identified non-mutational 
means of BRCA1 silencing or dysfunction in sporadic breast cancer, including methylation of 
the BRCA1 promoter and upregulation of microRNAs (miRNAs) that target the BRCA1 
transcript (Garcia et al., 2011; Moskwa et al., 2011).  Wei et. al. examined methylation of the 
ESR1 (estrogen receptor α), BRCA1 and FANCF promoters in a cohort of 120 sporadic primary 
breast cancers and noted that BRCA1 promoter methylation was present in 20% of their cohort.  
Methylation of BRCA1 was significantly correlated with methylation of ESR1, in agreement with 
findings that tumors with low or absent expression of BRCA1 are very commonly ER-negative 
(Wei et al., 2008b).  This same study only identified one out of the 120 breast cancers which 
exhibited FANCF promoter methylation.  Similarly, another study of Japanese primary breast 
cancers reported only four out of 99 primary tumors exhibiting FANCF promoter methylation 
(Tokunaga et al., 2009).  The FANCN/PALB2 promoter was identified to be methylated in only 
four of 60 sporadic breast cancers and 2 of 8 BRCA2-associated breast cancers (Potapova et al., 
2008).  Unlike methylation of FANCF and FANCN/PALB2, molecular changes affecting 
FANCC and FANCD2 expression are common in sporadic and hereditary breast cancer.  Sinha 
and colleagues collected 106 primary breast cancers and segregated them into early- and late-
onset cohorts (≤ 40 years of age and > 40 years of age, respectively) and examined deletions and 
promoter methylation in the 9q22.32-22.33 chromosomal region, which contains the FANCC 
gene and is altered in a wide variety of tumors.  Deletion or promoter methylation of the FANCC 
gene was observed in 53% of early-onset and 59% of late-onset tumors, suggesting that genetic 
and epigenetic alterations affecting FANCC expression are very common in both early- and late-
onset sporadic breast cancers.  Either form of alteration in FANCC was significantly associated 
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with deletion of BRCA2 in both early- and late-onset tumors but only with deletion of BRCA1 in 
early-onset tumors.  In both cohorts, patients with alterations in FANCC had poorer overall 
survival than those with intact and unmethylated FANCC genes (Sinha et al., 2008).  Conversely, 
van der Groep et. al. examined FANCD2 expression by immunohistochemistry in two cohorts of 
sporadic breast cancers and 25 BRCA1-associated breast cancers and correlated FANCD2 
immunopositivity with several clinicopathological features and prognosis (van der Groep et al., 
2008).  FANCD2 staining was positively correlated with Ki-67, cyclin A, mitotic activity index 
(MAI), and p53 staining, but negatively correlated with age, ER, and PR positivity.  The 
association between FANCD2 and proliferative markers was suggested to be a reflection of the 
biological function of FANCD2 in maintaining integrity of the genome during DNA replication.  
In a second cohort of 122 sporadic breast cancer cases with annotated survival data, high 
FANCD2 expression was associated with an unfavorable prognosis, and when analyzed with 
tumor size, lymph node status, ER and grade, FANCD2 appeared to have significant independent 
prognostic value for overall survival (van der Groep et al., 2008).  Interestingly, in the original 
cohort of 96 specimens, 19% and 10% of the sporadic and BRCA1-associated cases, respectively, 
stained completely negative for FANCD2.  It is likely that a genetic or epigenetic hit at the 
FANCD2 locus is responsible for loss of FANCD2 expression.  The lower incidence of FANCD2 
negativity in the BRCA1-associated cohort may be explained by reasoning that a second hit (i.e., 
in FANCD2) would be less advantageous for a cancer cell with a pre-existing hit in the same 
pathway (i.e., in BRCA1) than for one in which the entire FA/BRCA pathway is intact.  The 
authors in this study speculate that the link between high FANCD2 expression and poor 
prognosis may be a reflection of the high proliferative potential of these tumors, though it is 
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equally interesting to speculate that high FANCD2 expression confers intrinsic resistance to 
chemotherapy by way of increasing repair capacity (van der Groep et al., 2008). 
  
Ovarian Cancer 
As is the case with breast cancer, only 10-15% of all epithelial ovarian cancers (EOC) are 
hereditary in nature.  Unlike breast cancer, where first-line chemotherapy is often anthracycline-
based, EOCs have been treated with platinum-based regimens for several decades.  While 
anthracyclines are known to induce DSBs through inhibition of the re-ligation step of 
topoisomerase II (Tewey et al., 1984), repair of these lesions does not necessarily require the 
FA/BRCA pathway, as most DSBs in higher eukaryotes are repaired via non-homologous end 
joining (NHEJ) (Shrivastav et al., 2008).  Of note, anthracyclines can also form formaldehyde-
mediated covalent DNA adducts, and in vitro studies have suggested that HR, rather than NHEJ, 
plays a critical role in resolving this minor form of damage (Spencer et al., 2008).  Platinum-
based agents induce multiple forms of DNA damage as well, with approximately 96% of the 
damage being intrastrand crosslinks between 5’-GG-3’, 5’-AG-3’ and 5’-GNG-3’ nucleotides.  
The remaining 4% of the damage is interstrand crosslinks between antiparallel 5’-GC-3’ 
nucleotides on opposing strands (Eastman, 1986) (Figure 3).  Intrastrand crosslinks are repaired 
primarily by nucleotide excision repair (NER), while the interstrand crosslinks, though 
drastically less numerous, are more biologically toxic and require the FA/BRCA pathway to be 
repaired (Deans and West, 2011).  Because of the longstanding application of platinum-based 
agents in EOC, the necessity of the FA/BRCA pathway in repairing interstrand crosslinks, and 
the association of BRCA1/2 with hereditary ovarian cancer, this group of diseases has been much 
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more robustly studied with respect to FA/BRCA defects and chemosensitivity in both sporadic 
and hereditary malignancies. 
 
Similar to the early study on BRCA1/2-associated breast cancers (Chappuis et al., 2002), several 
early reports demonstrated that BRCA1- or BRCA2-associated ovarian cancers may be associated 
with a more favorable clinical course.  A study by Rubin et. al. of 53 advanced-stage EOC 
patients with a germline BRCA1 mutation noted median survival of 77 months, compared to 29 
months in non-BRCA1-associated advanced EOC patients (Rubin et al., 1996).  Similar results 
were obtained in a later study which reported that EOC patients heterozygous for either BRCA1 
or BRCA2 had higher response rates to primary therapy compared to sporadic cancers and that 
BRCA1/2 mutation-associated EOC patients had longer disease free survival (49 vs. 19 months) 
and overall survival (91 months vs. 54 months) than non-BRCA associated EOC (Cass et al., 
2003).  In contrast, a study examining BRCA1-associated breast and ovarian cancer reported an 
initial survival advantage in BRCA1-assocaited EOC that disappeared with time, ultimately 
suggesting a similar or potentially worse prognosis than sporadic EOC (Johannsson et al., 1998).  
These results are in concert with a study examining EOCs with BRCA1 dysfunction, defined as 
either documented mutation (germline or somatic) or BRCA1 promoter methylation leading to 
low or absent BRCA1 mRNA expression, in which no significant survival differences were 
noted between tumors based on BRCA1 functionality (Buller et al., 2002).  Despite these 
conflicting early reports, most contemporary studies have documented improved survival in EOC 
patients with BRCA1 or BRCA2 mutations compared to sporadic EOC (Gallagher et al., 2011; 
Lacour et al., 2011; Radosa et al., 2011; Tan et al., 2008; Vencken et al., 2011; Yang et al., 
2011). 
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Regarding sporadic EOCs and dysfunction of the FA/BRCA pathway, Taniguchi and colleagues 
proposed a model based on in vitro studies whereby platinum sensitive ovarian cancer cells have 
methylated the FANCF promoter, thus impairing monoubiquitination of FANCD2 (Figure 1, 
Step 2) and efficient interstrand crosslink repair.  This same study generated a cisplatin-resistant 
clone of a hypersensitive EOC cell line and demonstrated that the region immediately upstream 
of the FANCF transcriptional start site was almost globally unmethylated in the resistant cell line 
(Taniguchi et al., 2003).  In a cohort of 19 women with surgically resected primary ovarian 
tumors, this group identified methylation of FANCF in up to 21% of clinical specimens 
(Taniguchi et al., 2003).  This is comparable to studies by Wang and Lim demonstrating 
methylation of FANCF in 28% and 13% of primary ovarian cancers, respectively (Lim et al., 
2008; Wang et al., 2006).  The Wang study also noted that 67% of all specimens examined 
exhibited decreased FANCF protein expression (Wang et al., 2006).  Though inconsistent with in 
vitro data, the study by Lim et. al. noted that tumors with unmethylated FANCF exhibited a more 
favorable progression-free survival than those with methylated FANCF, though no association 
was seen with overall survival (Lim et al., 2008).  Another study by Teodoridis, et. al. aimed to 
examine methylation of FANCF,  BRCA1, and other candidate DNA repair genes in clinical EOC 
specimens.  Contrary to the studies by Taniguchi, Wang and Lim (Lim et al., 2008; Taniguchi et 
al., 2003; Wang et al., 2006), this group identified that none of the 106 stage III/IV EOCs in their 
cohort demonstrated FANCF promoter methylation, though BRCA1 promoter methylation was 
observed in 8.8% and 23.1% of the stage III and IV tumors, respectively (Teodoridis et al., 
2005).  Similarly, another study of 93 sporadic epithelial ovarian cancers only noted FANCF 
methylation in 3% of their specimens (Swisher et al., 2009).  The discrepancy between these 
studies with respect to FANCF methylation may be due to methodological differences, as well as 
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the fact that several studies may have included some germ cell tumors and not strictly EOCs.  
This is perhaps supported by another study conducted by Dhillon and colleagues which showed 
that 24% of ovarian germ cell tumors exhibited FANCF promoter methylation (Dhillon et al., 
2004).  In the Teodoridis study, tumors with BRCA1 methylation failed to fall into a cluster 
characterized by methylation of other genes, suggesting that BRCA1 methylation may occur by a 
distinct process or under a different selective pressure.  Methylation of at least one candidate 
gene involved in DNA repair (BRCA1, GSTP1 or MGMT) was significantly associated with 
response to chemotherapy, as 100% of patients with at least one of these three genes methylated 
responded to therapy.  When evaluating BRCA1 methylation independently of GSTP1 and 
MGMT, the difference was less robust, but still significant (Teodoridis et al., 2005).  In contrast, 
a comparatively small study examining survival with respect to BRCA1 promoter methylation 
found that sporadic tumors with BRCA1 methylation carried poorer prognosis than BRCA1-
mutation associated cancers or sporadic cancers with an unmethylated BRCA1 promoter (Chiang 
et al., 2006).  Though the results from this study are interesting, more numerous studies, 
including those with larger cohorts have since suggested that low BRCA1 expression is 
associated with prolonged survival.  One such study of 51 sporadic ovarian cancer patients 
receiving platinum-based chemotherapy reported median observed survival of 46 versus 33 
months for patients with lower and higher BRCA1 mRNA expression, respectively (Weberpals 
et al., 2009).  High BRCA1 mRNA expression appeared to be especially unfavorable in 
individuals with residual disease after surgical cytoreduction.  This pattern also emerged in a 
study by Quinn and colleagues who compared BRCA1 mRNA expression and survival in 
sporadic EOC and found that patients undergoing platinum-based chemotherapy with low or 
intermediate expression of BRCA1 mRNA had a mean 57.2 month overall survival compared to 
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18.2 months in those with high levels of BRCA1 mRNA expression (Quinn et al., 2007).  This 
study also found that BRCA1 mRNA expression, while inversely correlated to platinum 
sensitivity, was positively correlated with sensitivity to taxane-containing regimens.  BRCA1 is 
known to be required for G2/M arrest after microtubule poisons, and it has been shown in vitro 
that tumors with high expression of BRCA1 are sensitive to these agents, while deficiency of 
BRCA1 leads to relative resistance (Lafarge et al., 2001; Mullan et al., 2001; Quinn et al., 2003; 
Tassone et al., 2005).  Accordingly, in the poor prognosis cohort with high BRCA1 mRNA 
expression, addition of a taxane produced a trend for higher survival (23.0 versus 18.2 months) 
(Quinn et al., 2007).  Perhaps most convincing, a study of 115 sporadic ovarian cancers, 
including 31 which had paired pre- and post-chemotherapy samples, found that 34% and 42% of 
primary EOCs had low BRCA1 and BRCA2 protein expression, respectively (Swisher et al., 
2009).  Methylation of BRCA1 was only observed in 7% of this cohort, implying that loss of 
BRCA1 occurs most commonly by means other than promoter methylation.  As was observed in 
previous studies, loss of BRCA1 protein in primary neoplasms was associated with significantly 
better overall survival (62 months versus 45 months) than for tumors which retained BRCA1 
expression (Swisher et al., 2009), though there was no association between BRCA1 expression 
and likelihood of complete response to initial chemotherapy as was seen in a previous study 
(Taniguchi et al., 2003).  Moreover, for paired specimens in which the primary tumor exhibited 
low or intermediate BRCA1 or BRCA2, expression of these proteins was increased in 62% and 
71% of the recurrent carcinomas, respectively (Swisher et al., 2009).  As in sporadic breast 
cancer, methylation of the FANCN/PALB2 promoter in sporadic EOC appears to be relatively 
uncommon, with only four of 53 primary tumors exhibiting this epigenetic alteration in one 
study (Potapova et al., 2008).  Lastly, a recent clinical study by Konstantinopoulos and 
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colleagues established a “BRCAness” signature by interrogating gene expression data from 61 
EOC patients, 34 of whom were known to have BRCA1/2 mutations.  The classifier that emerged 
from this analysis was based on expression of sixty genes, of which notably, none are known to 
play significant roles in the FA/BRCA pathway.  When applied to another cohort of seventy 
patients with sporadic EOC, patients with the “BRCAness” profile had improved disease free and 
overall survival (34 versus 15 months and 72 versus 41 months, respectively) compared to 
patients whose tumors did not exhibit this signature (Konstantinopoulos et al., 2010).  Though 
the concept of “BRCAness” and differential sensitivity in familial and sporadic EOCs has been 
appreciated in both breast and ovarian cancer for over a decade, most of the prior methodologies 
used to define “BRCAness” relied on an assumption that the defect was mechanistically 
associated with HR (e.g., BRCA1/2 promoter methylation).  Because EOCs may evolve defects 
in HR by diverse mechanisms, this last study is notable in that it uses an approach which omits 
mechanistic assumptions and thus is poised to identify patients whose tumors exhibit defects in 
the HR pathway due to varied genetic or epigenetic perturbations. 
 
Assessing FA/BRCA Pathway Function 
In virtually all of the studies discussed, assessment of FA/BRCA function was made either 
retrospectively or incidentally during therapy, having been neither a prescribed diagnostic 
criterion nor having any bearing on clinical management of the patient.  It is nonetheless evident 
that dysfunction of the FA/BRCA pathway is relatively common in several prevalent cancers, 
and that, in select clinical scenarios, a priori knowledge of repair capacity may allow selection of 
more appropriate therapeutic agents and enable personalized cytotoxic chemotherapy, with the 
obvious advantage of improving clinical outcomes.  In order to make assessment of FA/BRCA 
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pathway integrity and function a reality, we must develop rapid assays that are informative of 
pathway function as a whole, do not require specialized instrumentation, and are both 
reproducible and relatively economical.  Several methodologies, including many that have been 
discussed, may be performed on preserved tissue or fluid specimens, while others will require an 
ex vivo genotoxic insult in order to measure the ability of cells to mount and/or execute an 
effective repair response.  Though implementation of such assays into clinical practice is not 
currently a reality, several studies have made promising strides in identifying potentially useful 
reporters of FA/BRCA pathway function. 
 
Following induction of a double-strand break (either directly by ionizing radiation or as part of 
the repair process of interstrand crosslinks), components of the FA/BRCA pathway will 
assemble into punctate nuclear foci (Figure 4).  Within minutes of sustaining a DSB, 
phosphorylated histone H2AX (serine 139) can be detected (Rogakou et al., 1998).  This is one 
of the earliest recognized markers that damage has been sustained, and this modified histone 
(designated γH2AX) serves as a docking site for components of the FA/BRCA pathway to 
initiate homology-directed repair (Figure 1).  Following successful resolution of the DSB, H2AX 
becomes dephosphorylated.  A recent study by Olive and Banáth examined the kinetics of 
γH2AX foci formation and response to cisplatin in several human and rodent cell lines with 
differential capacity to repair DNA damage.  They found that initial rates of H2AX 
phosphorylation were unrelated to drug sensitivity or proficiency in crosslink repair.  
Conversely, the fraction of cells that retained γH2AX foci at 24 hours after drug treatment (i.e., 
were unable to resolve damage) also had marked loss of clonogenic growth potential (Banath et 
al., 2004; Olive and Banath, 2009).  Thus, persistence of γH2AX foci formation at delayed 
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timepoints may be a sensitive marker of defective DNA repair and could represent a clinically 
feasible assay for identifying tumors which may be hypersensitive to DNA crosslinking agents or 
IR. 
 
Because of the large number of proteins that form the dynamic FA/BRCA complex, one could 
argue that examining the function of upstream components (i.e., FANCM or even γH2AX) could 
be less informative of overall pathway integrity than assessing function of critical downstream 
components.  Several studies have examined FANCD2 and RAD51 subnuclear localization with 
respect to chemosensitivity in vitro and in vivo.  A study by Willers and colleagues examined 
biomarkers related to FANCD2 function in virally immortalized fibroblasts from a patient with 
complementation group D2 Fanconi anemia and demonstrated that retroviral complementation of 
FANCD2 restored subnuclear FANCD2 assembly in response to DNA damage and conferred 
resistance to both MMC and H2O2 (Willers et al., 2008).  This same group soon published a 
report demonstrating the feasibility of assessing BRCA1, FANCD2 and RAD51 foci on fresh 
breast cancer biopsy specimens following ex vivo irradiation.  They examined seven locally 
advanced sporadic breast cancers for these biomarkers and reported that four of the seven 
exhibited a defective foci response (Willers et al., 2009).  Notably, three of the four tumors with 
defects were of the triple-negative phenotype, which as previously mentioned has been 
associated with BRCA1 deficiency (Turner and Reis-Filho, 2006; Turner et al., 2007).  After this 
small pilot study, Graeser et. al. examined RAD51 foci formation in 68 sporadic breast cancer 
patients who received neoadjuvant anthracycline-based chemotherapy.  In their study, patients 
underwent a core biopsy 24 hours after the first cycle of chemotherapy and this specimen was 
assessed for RAD51 subnuclear assembly by immunofluorescence microscopy.  Decreased 
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RAD51 focus formation was present in 26% of their specimens and correlated with high 
histologic grade, high baseline proliferation, and the triple-negative phenotype.  Importantly, a 
low RAD51 score was strongly predictive of response to therapy, with 33% of patients with low 
RAD51 achieving pCR compared with only 3% of patients with an intact RAD51 response 
(Graeser et al., 2010).  While somewhat invasive, this strategy has precedence in other tumors 
(e.g., osteosarcoma) and may be tremendously useful in predicting response and selecting 
appropriate chemotherapeutic agents.  Moreover, this type of analysis may be less technically 
challenging and more widely applicable for tumors in which neoplastic cells are more readily 
available for examination following chemotherapy (e.g., leukemic cells from blood and 
ovarian/peritoneal cancer cells from ascitic fluid in patients receiving intraperitoneal 
chemotherapy). 
 
An alternate means of assessing repair capacity is to examine not a molecular marker associated 
with repair, but the physical repair of DNA itself.  This task can be accomplished with relative 
ease using the single cell electrophoresis (comet) assay (Figure 5).  Undamaged genomic DNA 
from a single cell, when embedded in agarose and subjected to an electrical field, will migrate as 
an intact and roughly spherical mass.  Conversely, when various forms of damage are sustained, 
the physical structure of the DNA will change (e.g., fragmented after ionizing radiation or 
crosslinked after exposure to platinum-based agents).  The induction of such damage, as well as 
its repair can be observed and quantified using the comet assay.  
 
A study by Wynne and colleagues adapted the comet assay to examine DNA repair in 50 ovarian 
cancer patients whose cells (derived at surgical resection or from ascites) were treated ex vivo 
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with cisplatin.  Thirty-six of the patients in this cohort were newly diagnosed and treatment-
naïve, while 22 patients (some of whom were in the treatment-naïve cohort but had relapsed) had 
received previous chemotherapy.  No differences in peak levels of crosslinking were found 
between the treatment-naïve and previously treated patients, however, at 24 hours post ex vivo 
exposure to cisplatin, crosslink repair was significantly higher in the group of previously treated 
patients (86% exhibited >10% repair and 64% demonstrated >50% repair compared to 36% and 
3%, respectively, for the treatment-naïve group).  For eight patients it was possible to acquire 
tumor samples prior to chemotherapy and at relapse.  In these paired specimens, mean repair 
increased from 2.85% prior to chemotherapy to 71.23% in the specimens acquired after relapse, 
strongly arguing for DNA repair as a major mechanism in acquired chemotherapy resistance 
(Wynne et al., 2007).  A notable advantage of the comet assay over assays designed to quantify 
molecular beacons of damage or repair is that the assay is not subject to hypostatic confounders.  
That is, the assay measures the fundamental consequence of repair and does not rely on 
interpretation of molecular signals in the context of genetic or epigenetic alterations that may or 
may not be significant.  Indeed, the comet assay has been widely used to evaluate both risk and 
prognostication for diverse cancers as it is adept at detecting defects in pathways which ensure 
genomic stability without mechanistic assumptions as to the cause thereof (Berwick and Vineis, 
2000). 
 
Reversion Mutations and Acquired Resistance 
Acquired therapeutic resistance remains a major clinical obstacle in oncology.  In an effort to 
thwart the actions of chemotherapy and/or radiation, cancer cells are known to exploit membrane 
pumps to efflux drugs, inactivate apoptotic pathways, induce expression of detoxifying enzymes 
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and mutate the targets of antineoplastic agents.  While it has been appreciated that increased 
DNA repair likely contributes to acquired chemoresistance to DNA damaging agents, two 
landmark studies published simultaneously demonstrated that in vitro selection of BRCA2-
mutant ovarian and pancreatic cells resulted in outgrowth of cells that sustained intragenic frame 
restoring mutations at the BRCA2 locus (Edwards et al., 2008; Sakai et al., 2008).  To examine 
whether such a mechanism may confer resistance in vivo, Swisher and colleagues sequenced the 
BRCA1 gene in nine recurrent BRCA1-mutated ovarian cancers previously treated with 
chemotherapy.  Of these, one had primary resistance to platinum, five exhibited acquired 
platinum resistance, and three maintained sensitivity.  Four of the six recurrent platinum-resistant 
tumors had sustained secondary intragenic changes in BRCA1 that restored the BRCA1 reading 
frame, whereas none of the platinum-sensitive tumors exhibited changes in BRCA1 (Swisher et 
al., 2008). Another study by the same group examined BRCA2 sequence changes in three 
syngeneic cell lines that were established prior to and after the onset of platinum resistance in a 
BRCA2-mutant ovarian cancer.  The clone examined at the first relapse exhibited a BRCA2 
5193C>G (Y1655X) mutation and was sensitive to cisplatin, whereas two clones isolated from 
ascitic fluid at the second relapse and in the terminal stages of the disease both exhibited a 
5193C>T (Y1655Y) mutation that cancelled the effect of the inherited nonsense mutation, 
restored functional BRCA2 protein expression, and conferred resistance to platinum (Sakai et al., 
2009).  A very recent study by Swisher’s group examined the frequency of secondary BRCA1/2 
mutations in recurrent BRCA1/2-associated ovarian cancers.  This study evaluated 64 primary 
and 46 recurrent ovarian cancers and noted that 13 of the 46 (28%) recurrent tumors exhibited a 
secondary BRCA1 or BRCA2 mutation, and that these reversion events were nearly nine times 
more common in platinum-resistant recurrences than in those that remained platinum-sensitive.  
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Moreover, this study demonstrated that in women with recurrent ovarian cancer, those who had 
previously underwent chemotherapy for breast cancer also had higher frequency of secondary 
mutation in the recurrent ovarian lesion compared to those with no history of breast cancer 
(Norquist et al., 2011).  These studies confirm that intragenic mutations in BRCA1 and BRCA2 
are relatively frequent in vivo following chemotherapy of BRCA1/2-mutant ovarian cancers, 
argue that identification of such mutations can predict response to platinum-based agents, and 
strongly support a role for reversion mutation-induced repair-mediated resistance to platinum 
chemotherapy (Figure 6). 
 
Genetic and Pharmacologic Targeting of the FA/BRCA Pathway 
Many of the studies presented in this chapter support the idea that genetic or epigenetic 
interference of the FA/BRCA pathway sensitizes cells to DNA damaging agents that are 
commonly used in cancer therapy.  This is reinforced by studies showing that hyperactivity, 
overexpression or mutational restoration of components of this pathway is associated with 
acquired resistance.  Thus, genetic and/or pharmacologic inhibition of the FA/BRCA pathway 
may provide a new arsenal for the treatment of a number of malignancies, especially those that 
are refractory or exhibit acquired resistance to DNA damaging agents.  An early study by Ferrer 
et. al. developed an adenoviral vector encoding a dominant-negative (DN) form of FANCA that 
interfered with the endogenous FANCA-FANCG interaction and ultimately impaired FANCD2 
monoubiquitination.  Infection of a number of cell lines with DN FANCA adenovirus sensitized 
cell lines 2-3 fold to cisplatin (Ferrer et al., 2004).  Few studies have identified chemical agents 
that directly interfere with the FA/BRCA pathway.  A screen conducted by Chirnomas et. al. 
identified that four compounds (wortmannin (PI3K inhibitor), H-9 (PKC, -G and –A inhibitor), 
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alsterpaulone (GSK3β, CDK5/p25, and CDK1/Cyclin B inhibitor) and curcumin) were able to 
inhibit the FA/BRCA pathway.  Specifically, curcumin, a natural compound found in turmeric, 
was able to inhibit the monoubiquitination of FANCD2 and sensitize breast and ovarian cancer 
cell lines to cisplatin by causing apoptosis (Chirnomas et al., 2006).  Similarly, a study by 
Noguchi and colleagues reported impaired homologous recombinational repair of cancer cells 
treated with the heat shock protein 90 (HSP90) inhibitor 17-AAG that is currently in active 
clinical trials.  This study demonstrated that 17-AAG destabilized BRCA2 and in effect altered 
RAD51 expression and function (Noguchi et al., 2006).  Lastly, a study by Landais et. al. 
screened a chemical library for inhibitors of Xenopus FANCD2 monoubiquitination and 
identified 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone (DDN) as a novel potent inhibitor of 
the FA pathway.  DDN inhibited FANCD2 monoubiquitination of both human and Xenopus 
systems, inhibited subnuclear assembly of FANCD2 into foci, and displayed a synergistic effect 
with cisplatin in FA-proficient cancer cells (Landais et al., 2009).  Given the potential of 
synthetic lethal approaches, it is interesting to speculate that PARP inhibitors combined with 
novel pharmacologic inhibitors of the FA/BRCA pathway may prove to be highly effective anti-
neoplastic regimens. 
 
Discussion 
Our mechanistic understanding of DNA repair has benefited remarkably from studying Fanconi 
anemia and hereditary breast and/or ovarian cancer.  While inherited and acquired defects in the 
genes of the FA/BRCA pathway compromise genomic integrity and incite malignancy, these 
same alterations may represent an Achilles’ heel in tumors cells.  Perhaps the same genetic 
instability that epitomizes cancer and allows its incessant phenotypic evolution is also among its 
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most exploitable vulnerabilities. The immediate challenge is to identify, at the level of each 
patient, those tumors which exhibit compromised FA/BRCA pathway function and to tailor 
cytotoxic chemotherapy accordingly.  The relative frequency of acquired genetic and/or 
epigenetic alterations in this pathway suggests that double-strand break and interstrand crosslink 
repair are legitimate targets for therapeutic intervention or exploitation.  Moreover, novel 
therapeutic strategies aimed at crippling the activity of this pathway may show promise in 
preventing repair-mediated resistance to current cytotoxic agents.  A comprehensive 
understanding of FA/BRCA dysfunction in human cancers of both hereditary and sporadic 
nature, coupled with advances in diagnostic, genetic and pharmacologic tools to evaluate and 
manipulate expression or function of this pathway are certain to improve the clinical outcomes 
for patients with a number of cancers.  
 
In the coming chapters, we provide compelling evidence that BRCA1 is a novel client protein of 
HSP90 and that the clinically viable HSP90 inhibitor 17-AAG can regulate BRCA1-dependent 
repair of DSBs and ICLs.  These studies illuminate a novel mechanism to combat repair-
mediated resistance to platinum-based chemotherapy and ionizing radiation in breast, ovarian 
and potentially other malignancies.  We also report preliminary data on utilizing BRCA1 
promoter methylation as a predictive biomarker for response to anthracycline therapy in triple-
negative breast cancer, and speculate that platinum-based agents may yield more favorable 
clinical responses in a subset of BRCA1-deficient sporadic TNBCs. 
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Chapter II:  BRCA1 Stability and Function is Regulated by HSP90 
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Introudction 
Inherited mutations in the breast cancer susceptibility gene 1 (BRCA1) predispose to the 
development of breast, ovarian, and other malignancies (Ford et al., 1994; Friedman et al., 1994; 
Hall et al., 1990; King et al., 2003; Thompson et al., 1995).  BRCA1 is a nuclear phosphoprotein 
with broad tumor suppressor activities and is known to play a critical role in the repair of double-
strand DNA breaks (DSBs) and interstrand crosslinks (ICLs) by homologous recombination 
(HR) (Huen et al.).  Upon induction of DSBs or ICLs, BRCA1 is phosphorylated by ATM, ATR, 
and CHK2 kinases and appears to recruit and organize multiple distinct protein complexes that 
recognize and repair damaged DNA and activate cell cycle checkpoints (Cortez et al., 1999; 
Yarden et al., 2002).   
 
Therapeutic strategies based on synthetic lethality have emerged that target cells deficient in 
DSB repair (reviewed in Chapter I).  These approaches exploit the fact that inherited or acquired 
defects in a single pathway, such as BRCA1-dependent DSB repair, may have few or no 
deleterious effects on cellular function due to the action of another redundant or adaptive path-
way.  However, simultaneous inactivation of an ancillary pathway that rescues DSB repair-
deficient cells will lead to accumulation of unrepaired DNA damage and cell death.  Specifically, 
the DSB repair-deficient cancers arising in BRCA1 mutation carriers are highly sensitive to 
inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme critical in base excision repair 
(Adhikari et al., 2008).  Clinical trials employing PARP inhibitors are currently ongoing and 
these agents show promise in the treatment of BRCA1 and BRCA2-associated breast, ovarian and 
prostate cancers, as well as sporadic basal-like breast cancers, which are thought to have 
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dysfunction of the BRCA1 pathway in the absence of mutations at its genetic locus (Fong et al.; 
Turner et al., 2007). 
 
In light of the body of evidence suggesting that high BRCA1 expression in both breast and 
ovarian cancers contributes to therapeutic resistance, there has been much interest in identifying 
agents which interfere with BRCA1-dependent DNA damage repair.  In the current study, we 
have identified BRCA1 as a novel client protein of heat shock protein 90 (HSP90) and 
demonstrate that pharmacologic inhibition of HSP90 using 17-allylamino-17-
demethoxygeldanamycin (17-AAG) results in profound loss of BRCA1 expression and function.  
HSP90 is an evolutionarily conserved chaperone that promotes the proper folding of client 
proteins, thereby regulating their stability, expression, trafficking and function (Whitesell and 
Lindquist, 2005).  Simultaneous disruption of signaling nodes that regulate all hallmarks of 
cancer can be achieved by inhibition of HSP90 (Blagg and Kerr, 2006; Hanahan and Weinberg, 
2000).  Natural compounds including geldanamycin, radicicol and novobiocin have been 
identified to bind the N- or C-terminal ATP-binding pockets of HSP90 and disrupt its chaperone 
function, leading to client protein degradation via the ubiquitin-proteasome pathway (Blagg and 
Kerr, 2006).  Semi-synthetic analogues of geldanamycin, including 17-AAG, as well as newer 
generation HSP90 inhibitors are undergoing clinical trials for the treatment of a variety of human 
malignancies (Kim et al., 2009).  These inhibitors have shown promise in sensitizing tumor cells 
to numerous genotoxic agents which are commonly used in cancer therapy, including DNA 
alkylating agents, ionizing radiation, DNA replication inhibitors and PARP inhibitors 
(Camphausen and Tofilon, 2007; Dungey et al., 2009). 
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The ability of HSP90 inhibitors to potentiate cells to ionizing radiation and chemotherapeutic 
agents can be explained by the critical role of HSP90 in stabilizing and/or activating components 
of the HR/ICLR and non-homologous end joining (NHEJ) DSB repair machinery, including 
CHK1, BRCA2, RAD51, FANCA, and DNA-PKcs (Arlander et al., 2003; Dote et al., 2006; 
Noguchi et al., 2006; Oda et al., 2007).  Except for DNA-PKcs, the activity and/or recruitment of 
these molecules to sites of DNA damage is dependent on BRCA1 function (Bhattacharyya et al., 
2000; Chen et al., 2008; D'Andrea and Grompe, 2003; Folias et al., 2002; Yarden et al., 2002; 
Zhang et al., 2009; Zhong et al., 1999).  We report here that pharmacologic inhibition of HSP90 
results in rapid loss of BRCA1 through the ubiquitin-proteasome pathway, subsequent failure of 
BRCA1 to assemble at ionizing radiation-induced foci (IRIF), and functional defects in both HR 
and NHEJ.  In summary, while previous studies have documented defects in HR and NHEJ as a 
consequence of inhibiting HSP90, we provide direct evidence that loss of BRCA1 following 
inhibition of HSP90 is a key event leading to defective DSB repair and potentiation to DNA 
damaging agents. 
 
Materials and Methods 
Cell Culture 
All cell lines were obtained from and cultured according to ATCC recommendations.  
 
Adenoviruses and Adenoviral Production 
The coding region of the I-SceI endonuclease with two 5’ nuclear localization signals and a 
hemagglutnin (HA) tag was excised from the pCBASce plasmid as an XbaI/MscI fragment and 
cloned into pShuttle-CMV which had been digested with XbaI and EcoRV.  The pShuttle-CMV-
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I-SceI plasmid was then digested with PmeI, desalted by Qiaex, and then electroporated into E. 
coli strain BJ5183 along with pAdEasy1 to allow homologous recombination to occur (He et al., 
1998).  The resultant vector was PacI linearized and was transfected into AD293 cells.  
Adenoviral supernatants were produced by freeze/thaw and sonication and were titered using the 
Adeno-X Rapid Titer Kit (Clontech).  The HA-tagged wild-type and deletion mutant 
adenoviruses (Chiba and Parvin, 2002) were a kind gift from Jeffrey Parvin (The Ohio State 
University Medical Center) and were produced as describe above. 
 
Lentivirus Generation and Infection 
The Expression Arrest™ GIPZ lentiviral shRNAmiR library targeting BRCA1 and control GIPZ 
vector were purchased from OpenBiosystems (ThermoFisher Scientific, Waltham, MA).  
Lentiviruses were packaged in HEK293T cells using pRC-CMV-RaII, pHDM-tat16, pHDM-
HG-PM2, and pHDM-VSVG packaging constructs.  Supernatants were ultracentrifuged and 
infectious particles were titered by flow cytometry according to the equation   
   
   
 , where T 
equals titer in transducing units (TU) per mL, P equals the percentage of GFP
+
 cells, N equals 
the number of cells at the time of transduction, D equals the dilution of virus, and V equals the 
volume of viral inoculum in mL.  MCF7 cells were infected at a multiplicity of infection (MOI) 
of 0.2 according to the equation    
    
 
, where V equals the volume of stock virus required in 
mL, C equals the number of cells being infected, MOI equals the desired multiplicity of 
infection, and T equals titer (in TU/mL) calculated as described above.  Cells were selected for 
two weeks in 2 µg/mL puromycin and were maintained in selective media for the duration of all 
experiments. 
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Drug Treatment 
17-AAG was purchased from InvivoGen, radicicol was purchased from Tocris, novobiocin, 
cycloheximide, carboplatin and MG132 were purchased from Sigma-Aldrich.  Carboplatin was 
dissolved in PBS, all other drugs were dissolved in DMSO. 
 
Irradiation 
Cells were irradiated using a 
137
Cs source irradiator at a dose rate of 4.97 Gy·min
-1
. 
 
DNA Foci Formation Assay 
Cells were grown in 8-well chamber slides, treated and exposed to 0 or 10 Gy ionizing radiation.  
Fixative was 4% paraformaldehyde with 3% sucrose on ice for 30 minutes.  Permeabilizer was 
0.1% Triton X-100 in PBS for five minutes at room temperature.  Cells were blocked with 
blocking buffer (1% bovine serum albumin (fraction V), 3% goat serum, and 0.1% Triton X-100) 
for two hours at 4°C.  Primary antibodies were diluted in blocking buffer (BRCA1 Ab1 (1:200), 
γH2AX (1:1000)) and incubated on fixed/permeabilized cells overnight at 4°C.  Secondary 
antibody was goat anti-mouse Alexa 594 (Invitrogen/Molecular Probes) diluted in blocking 
buffer at 1:1000.  Nuclei were counterstained with DAPI (Sigma-Aldrich) at 50 ng/mL for thirty 
minutes.  Foci formation was quantitated using the Zeiss Pascal confocal software by 
normalizing the fluorescent signal for γH2AX or BRCA1 to the DAPI signal. 
 
Homologous Recombination and Non-Homologous End Joining 
The DR-GFP reporter construct, pCBASce (I-SceI) and pCAGGS (empty control) vectors were 
kindly provided by Maria Jasin (Memorial Sloan-Kettering Cancer Center).  This assay was 
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performed essentially as previously described (Nakanishi et al., 2005).  Briefly, HeLa cells were 
transfected with the DR-GFP reporter plasmid, selected with 5 µg/mL puromycin, and cloned.  
The I-SceI or empty control vector were electroporated into the  HeLa-DR-GFP cells (1 
µg/1x10
5
) cells using the Amaxa nucleofector system (Lonza, Walkersville, MD) and cells were 
immediately plated into 250 nM 17-AAG or DMSO.  After 24 hours, the drug was removed and 
replaced with fresh media for an additional 24 hours.  Cells were trypsinized and HR was 
measured by assessing number of GFP+ cells on a BD LSR II flow cytometer.  Genomic DNA 
was isolated from a fraction of the treated cells using the DNeasy Blood and Tissue Kit from 
Qiagen and used as the template for PCR with the following primers: DRGFP-F, 5’-
CTGCTAACCATGTTCATGCC-3’ and DRGFP-R, 5’-AAGTCGTGCTGCTTATGTG-3’.  PCR 
conditions were one cycle for one minute at 94°C for initial denaturation; 35 cycles for 20 
seconds at 94°C for denaturation, then 40 seconds at 54°C for annealing, and 40 seconds at 72°C 
for extension; and one cycle for 7 minutes at 72°C for final extension.  PCR products were 
purified using the QIAquick Purification Kit (Qiagen) and then digested with 10 units of I-SceI 
(New England Biolabs) for 16 hours at 37°C and then heat inactivated at 65°C for 20 minutes.  A 
half-volume of the product was subsequently digested with 20 units of BcgI for four hours at 
37°C and then heat inactivated at 65°C for 20 minutes.  Samples were electrophoresed on a 1.2% 
agarose gel in 1X TAE and the gel was stained with ethidium bromide.  Digested products were 
visualized and quantitated using the UVP BioImaging System (UVP). 
 
Antibodies 
Mouse anti-Actin (#MAB1501, Upstate/Millipore), mouse anti-BARD1 (#ab50984, Abcam), 
mouse anti-BRCA1 (Ab1) (#OP92, Calbiochem/EMD Biosciences), rabbit anti-BRCA1 (C-20) 
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(#sc-642, Santa Cruz Biotechnology), mouse anti-phospho-Histone H2A.X (Ser139) (γH2AX) 
(#05-636, Upstate/Millipore), mouse anti-HSP90 (#05-594, Upstate/Millipore), mouse anti-
HSP90 (#ADI-SPA-830, Stressgen), mouse anti-Ubiquitin (#13-1600, Invitrogen), anti-HA 
(#H3663, Sigma-Aldrich), anti-rabbit HRP-linked (#7074, Cell Signaling Technology) and anti-
mouse HRP-linked (#7076, Cell Signaling Technology). 
 
Immunoprecipitation and Western Blot 
Protein was harvested using a modified RIPA buffer (50 mM Tris base, 150 mM NaCl, 2 mM 
EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM NaF, 5 mM Na3VO4, 
plus 1X protease inhibitor cocktail (Sigma-Aldrich)), quantified using the DC protein assay (Bio-
Rad), electrophoresed on 8% or 4-12% tris-glycine gels (Invitrogen) and then transferred onto 
PVDF membranes.  All blocking steps and antibody-dilutions were in 3% non-fat dairy milk in 
PBS + 0.1% Tween-20. Densitometry calculations were made using the UVP BioImaging 
System.  For IP, cells were lysed in IP buffer (20 mM Tris-HCl (pH 7.5-7.9), 100 mM NaCl, 
0.05% NP-40, 1 mM PMSF), immunoprecipitated with 10 μg antibody overnight at 4°C on a 
rotating platform.  Complexes were bound to Protein-A agarose beads (#15918-014, Invitrogen), 
washed and eluted according to manufacturer’s protocol. 
 
Results 
HSP90 Interacts with BRCA1 and is Necessary for its Stability 
To understand the regulatory properties of HSP90 on BRCA1 expression, we examined the 
effects of 17-AAG treatment on BRCA1 in MCF7 breast cancer cells.  17-AAG downregulated 
BRCA1 in a dose- and time-dependent manner (Figure 1A-B), and when combined with 
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cycloheximide, increased the rate of BRCA1 decay in HCC1937
BRCA1
 cells beyond that observed 
with cycloheximide alone (Figure 2).  Transcriptional activation of the BRCA1 promoter and 
levels of BRCA1 mRNA showed delayed effects, with a marginal increase in expression of 
BRCA1 promoter-driven luciferase 24 hours post treatment and a progressive loss of reporter 
transactivation by 48 and 72 hours (Figure 3).  Furthermore, BRCA1 protein degradation 
preceded loss of BRCA1 mRNA (Figure 4), suggesting that destabilization of BRCA1 protein is 
likely the major mechanism for BRCA1 loss in response to 17-AAG, though transcriptional 
downregulation may contribute to loss of BRCA1 at later timepoints.  17-AAG treatment also 
increased expression of HSP90 mRNA and protein (Figure 1A-B and 4), reflecting a previously 
described feedback stimulation of stress-responsive genes (McCollum et al., 2008).   17-AAG 
treatment did not simultaneously alter expression of the constitutively associated BRCA1-
Associated Ring Domain 1 (BARD1) protein, which is necessary for BRCA1 stability and 
function (Figure 5) (Joukov et al., 2001).  Kinetic studies in SK-BR-3 (HER2
+
 breast cancer cell 
line), MDA-MB-231 (triple-negative breast cancer cell line), SK-OV-3 (ovarian 
cystadenocarcinoma cell line) and HT-29 (colorectal adenocarcinoma cell line) cells revealed 
that 17-AAG induced degradation of BRCA1 expression in all cell lines tested (Figure 6A).  
Treatment of MCF7 cells with radicicol and novobiocin, two additional inhibitors of HSP90 
chaperone function, also resulted in loss of BRCA1 (Figure 6B).   
 
These data suggest that BRCA1 may be a client protein of HSP90.  Co-immunoprecipitation 
studies revealed that BRCA1 and HSP90 interact at basal levels, that irradiation of cells 
increases the association between BRCA1 and HSP90, and that treatment with 17-AAG can 
abolish this interaction (Figure 7).  We were unable to reproducibly demonstrate the interaction 
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in the opposite direction, implying that the bulk of cellular BRCA1 may not be constitutively 
associated with HSP90.  To evaluate functional regions that may be important in mediating 17-
AAG-induced BRCA1 degradation, we evaluated the effect of 17-AAG on MCF7 cells infected 
with HA-tagged BRCA1 wild-type and deletion mutant expressing adenoviruses.  We observed 
that amino acids 775-1292 are likely important in mediating 17-AAG-induced BRCA1 
degradation, as exogenously expressed protein lacking this domain appeared to be stable in the 
presence of 17-AAG (Figure 8).  Assessment of the effect of 17-AAG on a large N-terminal 
truncation (Δ1-302) was not possible, as this mutant is unable to bind to BARD1 and would be 
expected to be highly unstable (Figure 8) (McCarthy et al., 2003).  Inhibition of HSP90 induces 
polyubiquitination and proteasomal degradation of proteins that are dependent on HSP90 
chaperone function (Blagg and Kerr, 2006).  To examine ubiquitination of BRCA1 in response to 
17-AAG, we treated MCF7 cells with 10 µM of the 26S proteasome inhibitor MG132, 250 nM 
17-AAG, or both for two hours and immunoprecipitated BRCA1.  This duration of 17-AAG 
treatment alone had no detectable effect on BRCA1 levels (consistent with data in Figure 1), 
while treatment with MG132 alone resulted in mild accumulation of polyubiquitinated BRCA1, 
supporting previous observations that the ubiquitin-proteasome pathway is involved in regulating 
basal levels of BRCA1 (Figure 9A) (Choudhury et al., 2004).  Simultaneous treatment with 17-
AAG and MG132 led to robust accumulation of polyubiquinated BRCA1 (Figure 9A).  We 
confirmed that pre-treatment with MG132 for one hour followed by 250 nM 17-AAG for an 
additional eight hours partially rescued BRCA1 from degradation (Figure 9B).  Taken together, 
these results suggest that the chaperone activity of HSP90 is required to maintain expression of 
BRCA1 and that inhibition of HSP90 activity induces the polyubiquitination and subsequent 
proteasomal degradation of BRCA1. 
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Inhibition of HSP90 Impairs Assembly of BRCA1 to Ionizing Radiation-Induced Foci 
Recruitment of BRCA1 to sites of DNA damage is a dynamic process involving a large number 
of proteins (Shrivastav et al., 2008).  Induction of DSBs leads to the rapid phosphorylation of 
histone H2AX by ATM (γH2AX) (Burma et al., 2001).  This phosphorylation event induces 
ubiquitination of γH2AX and subsequent recruitment of a number proteins required for the 
stability and assembly of the DSB repair complex, including RAP80, ABRA1, MERIT40, 
BRCC36, BRCC45, BRCA1, and BARD1 (Huen et al.).  To assess whether inhibiting HSP90 
affects upstream DSB signaling and/or assembly of BRCA1 to sites of DNA damage, we treated 
MCF7 cells with DMSO or 250 nM 17-AAG for 24 hours, exposed them to 10 Gy of IR and 
immunostained for γH2AX and BRCA1.  MCF7 cells infected with lentiviruses expressing 
control or BRCA1-targeting shRNA were included as controls.  Treatment with 17-AAG prior to 
IR did not prevent, but rather augmented γH2AX foci formation (Figure 10A, compare iii and iv) 
but significantly interfered with assembly of BRCA1 to IRIF (Figure 10B, compare iii and iv).  
Interestingly, treatment with 17-AAG in the absence of IR also induced γH2AX foci formation 
(Figure 10A, compare i and ii), suggesting that 17-AAG may lead to accumulation of 
spontaneous DSBs by inhibiting basal DSB repair.  This effect of 17-AAG is likely independent 
of its effect on BRCA1 expression, as shRNA-mediated BRCA1 ablation did not increase 
γH2AX foci formation above baseline (Figure 10A, compare v and vi).  These results 
demonstrate that HSP90 inhibition causes failed localization of BRCA1 to sites of DSBs while 
simultaneously causing accumulation of DSBs and/or augmenting early signaling events 
associated with DSB induction.  Importantly, while the expression or localization of other 
components of the HR DSB repair complex are known to be affected by inhibiting HSP90 
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(Arlander et al., 2003; Dote et al., 2006; Noguchi et al., 2006; Oda et al., 2007), BRCA1 is 
required for the recruitment and function of all of these components (Bhattacharyya et al., 2000; 
Chen et al., 2008; D'Andrea and Grompe, 2003; Folias et al., 2002; Yarden et al., 2002; Zhang et 
al., 2009).  Thus, our data suggest that loss of BRCA1 is a key upstream event leading to failure 
of DSB repair processes following inhibition of HSP90. 
 
Inhibition of HSP90 Impairs Both Homologous Recombination and Non-Homologous End 
Joining 
To functionally assess DSB repair capacity following treatment with 17-AAG, we employed a 
DSB repair reporter system (Figure 11A) (Nakanishi et al., 2005).  To preclude the possibility 
that 17-AAG treatment would interfere with expression of I-SceI (and thus not permit valid 
interrogation of DSB repair using this assay), we evaluated the effect of 17-AAG treatment on 
expression of HA-tagged I-SceI.  No difference in I-SceI stability was noted in the presence or 
absence of 17-AAG, excluding the possibility that observed differences in HR efficiency are due 
to impaired induction of DSBs in 17-AAG treated cells (Figure 11B).  We used HeLa cells for 
this assay as they demonstrate more robust capacity for HR than do MCF7 cells, express higher 
levels of BRCA1, and have been used to examine BRCA1-associated defects in HR (Kachhap et 
al., 2001; Ransburgh et al., 2010).  HeLa cells which had been stably selected to contain the DR-
GFP reporter construct were electroporated with a control vector (Figure 12i and ii) or a vector 
encoding I-SceI (Figure 12iii and iv) and were immediately plated into media containing DMSO 
(Figure 12i and iii) or 250 nM 17-AAG (Figure 12ii and iv).  Approximately 14.8% of the 
vehicle-treated cells expressing I-SceI exhibited HR (Figure 12iii), while 0.4% of those treated 
with 17-AAG completed HR (Figure 12iv).  To confirm reduced HR and to assess the 
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contribution of NHEJ to DSB repair following I-SceI expression, we performed PCR 
amplification and enzymatic digestion of repair products from genomic DNA isolated from the 
reporter HeLa cells.  Amplification of the region indicated by arrows in Figure 11A will generate 
a 0.65 kb fragment.  Total repair product (i.e., repaired by either HR or NHEJ) can be visualized 
as the relative amount of PCR product that remains uncut following digestion with I-SceI (Figure 
13A, “s1”).  Vehicle-treated HeLa cells expressing I-SceI demonstrated robust DSB repair 
(62.5%), while those treated with 17-AAG had profoundly lower total repair product (3.3%) 
(Figure 13A, compare “s1” and “s2”).  Subsequent digestion of the I-SceI-cleaved product with 
BcgI will delineate the individual contributions of HR and NHEJ to total DSB repair.  From 
these data, it was calculated that in vehicle-treated cells, approximately 75% of total repair 
product was repaired by NHEJ, while 25% was repaired by HR (Figure 13B, left).  While 17-
AAG significantly interfered with both HR and NHEJ, the distribution of repair pathway choice 
was only marginally skewed, with 86% and 14% repaired by NHEJ and HR, respectively (Figure 
13B, right).  These values are consistent with the flow cytometric assay of HR, as 25% of 62.5%, 
and 14% of 3.3% for DMSO and 17-AAG treated cells, respectively, would generate expected 
GFP+ frequencies of 15.6% and 0.5% (compared to the observed 14.8% and 0.4%).  These data 
provide functional support of our finding that 17-AAG impairs BRCA1 expression and function 
and supports previous studies suggesting that HSP90 is required for both HR and NHEJ (Dote et 
al., 2006; Noguchi et al., 2006; Oda et al., 2007). 
 
Discussion 
In this chapter, we have demonstrated that the HSP90 chaperone is required for maintenance of 
BRCA1 expression and function.  To our knowledge, this study is the first to document a 
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functional link between HSP90 and BRCA1.  Specifically, we demonstrated that pharmacologic 
inhibition of HSP90 using the clinically-relevant inhibitor 17-AAG results in destabilization and 
proteasomal degradation of BRCA1.  In an attempt to test the alternative hypothesis that HSP90 
regulates BRCA1 stability indirectly, we evaluated the expression of BARD1, a constitutive 
BRCA1 binding partner that is known to be critical for BRCA1 stability (Joukov et al., 2001).  
BARD1 downregulation was significantly delayed compared to BRCA1 degradation and is 
likely due to destabilization of BRCA1 rather than a direct consequence of HSP90 inhibition. 
 
Prior to our study, a single report suggested a link between BRCA1 and the heat shock response 
(Xian Ma et al., 2003).  This report showed that BRCA1 plays a protective role in heat toxicity 
and that thermal stress induces BRCA1 degradation.  While this study observed profound 
destabilization of BRCA1 in breast and prostate cancer cells in response to incubation at 42°C, 
they were unable to rescue BRCA1 protein levels by inhibiting any of the well-characterized 
pathways that mediate protein degradation, including the ubiquitin-proteasome pathway.  Thus, 
our results, which document that the ubiquitin-proteasome pathway is responsible for BRCA1 
degradation suggests that the mechanism of BRCA1 degradation in response to heat shock is 
quite distinct from the mechanism of BRCA1 degradation in response to heat shock protein 90 
inhibitors. 
 
Our study also documents that HSP90 inhibitors prevent the localization of BRCA1 to IRIF.  
While previous studies have described failed homology-directed repair of DSBs after inhibition 
of HSP90, these studies have focused on the effects of HSP90 inhibitors on BRCA2, RAD51, 
FANCA, CHK1, and the MRE11/RAD50/NBS1 (MRN) complex (Arlander et al., 2003; Dote et 
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al., 2006; Noguchi et al., 2006; Oda et al., 2007).  Importantly, the function of each of these 
molecules is dependent upon BRCA1.  Specifically, evidence suggests that BRCA2, RAD51, 
and the MRN complex fail to assemble in the absence of BRCA1 (Bhattacharyya et al., 2000; 
Zhang et al., 2009; Zhong et al., 1999).  Furthermore, BRCA1 is necessary for activation of 
CHK1 kinase which is critical in inducing G2/M arrest following DNA damage and functioning 
in concert to facilitate the monoubiquitination of FANCD2 (Guervilly et al., 2008; Yarden et al., 
2002).  Thus, of the HR/ICLR repair proteins that have been identified to be sensitive to HSP90 
inhibitors, BRCA1 appears to be the most upstream. 
 
As modeled in Figure 14, certain types of DNA damage caused by chemical or physical agents 
induce BRCA1 expression and localization to sites of DSBs, ultimately resulting in DNA repair 
by either HR/ICLR or NHEJ.  While this sequence of events is protective and desirable in 
normal tissue, hyperactivity of these BRCA1-dependent DNA damage repair complexes can 
confer resistance to cancer therapeutics, thus the therapeutic benefit of traditional genotoxic 
agents is likely stunted by the action(s) of BRCA1 and its associated proteins.  Agents which 
inhibit the BRCA1-dependent DNA damage repair machinery may find success in enhancing or 
restoring sensitivity to therapeutic agents in both the adjuvant and salvage therapy settings.  
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Chapter III:  BRCA1 Regulates 17-AAG-Induced Radio- and Chemosensitization, G2/M 
Checkpoint Activation, Replication Stress Response and Apoptosis 
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Introduction 
BRCA1 is a critical determinant of homology directed repair of double-strand DNA lesions 
arising from ionizing radiation (IR) and interstrand crosslinks (ICLs) and also prevents collapse 
and promotes error-free bypass of stalled replication forks by sister chromatid exchange.  
Though BRCA1 is a tumor suppressor and is critical for genomic integrity, in vitro, in vivo and 
human clinical studies have shown that tumor cells expressing high levels of BRCA1 are 
resistant to IR and several classes of chemotherapeutic agents and that ablation of BRCA1 
expression in resistant cell lines can restore sensitivity to these agents (Abbott et al., 1999; Scata 
and El-Deiry, 2007).  Consistent with these findings, cancers arising in BRCA1 mutation carriers 
are profoundly sensitive to platinum-based therapies while high BRCA1 mRNA expression in 
sporadic cancers is a biomarker for poor response to these same agents (Bhattacharyya et al., 
2000; Husain et al., 1998; Silver et al.).  Since BRCA1 is critical for resolving double-strand 
breaks (DSBs) and ICLs, cells with exaggerated BRCA1 expression are likely selected for during 
treatment with genotoxic agents both in vitro and in vivo.  While BRCA1- and BRCA2-deficient 
cancers are profoundly sensitive to platinum-based therapies and PARP inhibitors, recent studies 
of BRCA1/2-associated human ovarian cancers have revealed that therapy-induced secondary 
mutations which restore the BRCA1 or BRCA2 reading frames occur with significant frequency 
and are directly responsible for resistance to platinum-based therapies and PARP inhibitors 
(Ashworth, 2008; Swisher et al., 2008).  Thus, targeting BRCA1 and/or its associated protein 
complexes in cancer chemo- and radiotherapy may induce hypersensitivity to agents which 
induce DSBs and prevent the development or recurrence of resistant disease (Chen et al., 2006).   
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In this chapter, we investigated the ability of the HSP90 inhibitor 17-AAG to enhance or restore 
sensitivity to ionizing radiation and carboplatin in several models.  We demonstrate that 
lentiviral knockdown of BRCA1 or inhibition of HSP90 with 17-AAG leads to hypersensitivity 
to ionizing radiation in MCF7 breast cancer cells, and that loss of BRCA1 is epistatic to the 
ability of 17-AAG to further sensitize cells to radiation.  Moreover, we show that genetic 
complementation of wild-type BRCA1 into BRCA1-mutant ovarian and breast cancer cells 
induces resistance to carboplatin, and that 17-AAG can reverse this resistance.  We extend these 
studies to show that 17-AAG can also sensitize sporadic platinum-resistant ovarian cancer cells.  
In summary, we demonstrate the therapeutic utility of ablating BRCA1 and identify a novel 
approach to reversing platinum and radiation resistance in both breast and ovarian cancer. 
 
Materials and Methods 
Cell Culture 
A2780, CP70 and C30 cells were provided by Andrew Godwin (University of Kansas Medical 
Center).  HCC1937 and HCC1937
BRCA1
 cells were a gift from Junjie Chen (MD Anderson 
Cancer Center).  All five lines were grown in RPMI-1640 supplemented with 10% FBS and 
penicillin/streptomycin.  All other cell lines were obtained from ATCC.  Culture of all cell lines 
was performed per ATCC recommendations. 
 
Lentivirus Generation and Infection 
The Expression Arrest™ GIPZ lentiviral shRNAmiR library targeting BRCA1 and control GIPZ 
vector were purchased from OpenBiosystems (ThermoFisher Scientific, Waltham, MA).  
Lentiviruses were packaged in HEK293T cells using pRC-CMV-RaII, pHDM-tat16, pHDM-
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HG-PM2, and pHDM-VSVG packaging constructs.  Supernatants were ultracentrifuged and 
infectious particles were titered by flow cytometry according to the equation   
   
   
 , where T 
equals titer in transducing units (TU) per mL, P equals the percentage of GFP
+
 cells, N equals 
the number of cells at the time of transduction, D equals the dilution of virus, and V equals the 
volume of viral inoculum in mL.  MCF7 cells were infected at a multiplicity of infection (MOI) 
of 0.2 according to the equation    
    
 
, where V equals the volume of stock virus required in 
mL, C equals the number of cells being infected, MOI equals the desired multiplicity of 
infection, and T equals titer (in TU/mL) calculated as described above.  Cells were selected for 
two weeks in 2 µg/mL puromycin and were maintained in selective media for the duration of all 
experiments. 
 
Drug Treatment 
17-AAG was purchased from InvivoGen and dissolved in DMSO.  Carboplatin was purchased 
from Sigma-Aldrich and was dissolved in PBS. 
 
Irradiation 
Cells were irradiated using a 
137
Cs source irradiator at a dose rate of 4.97 Gy·min
-1
. 
 
Antibodies 
Mouse anti-Actin (#MAB1501, Upstate/Millipore), mouse anti-BRCA1 (Ab1) (#OP92, 
Calbiochem/EMD Biosciences), mouse anti-HSP70 (#610608, BD Biosciences), mouse anti-
HSP27 (#2402, Cell Signaling Technology), rabbit anti-HSF1 (#4356, Cell Signaling 
Technology), mouse anti-CHK1 (#2360, Cell Signaling Technology), rabbit anti-pCHK1
S345 
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(#2341, Cell Signaling Technology), rabbit anti-cyclin B1 (#sc-752, Santa Cruz Biotechnology), 
rabbit anti-H3 (#9715, Cell Signaling Technology), rabbit anti-pH3
S10
 (#9701, Cell Signaling 
Technology), Alexa®-488 anti-pH3
S28
 (#558610, BD Biosciences), anti-rabbit HRP-linked 
(#7074, Cell Signaling Technology) and anti-mouse HRP-linked (#7076, Cell Signaling 
Technology). 
 
Western Blot 
Protein was harvested using a modified RIPA buffer (50 mM Tris base, 150 mM NaCl, 2 mM 
EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM NaF, 5 mM Na3VO4, 
plus 1X protease inhibitor cocktail (Sigma-Aldrich)), quantified using the DC protein assay (Bio-
Rad), electrophoresed on 8% or 4-12% tris-glycine gels (Invitrogen) and then transferred onto 
PVDF membranes.  All blocking steps and antibody-dilutions were in 3% non-fat dairy milk in 
PBS + 0.1% Tween-20. 
 
Clonogenicity Assay 
MCF7 cells infected with control or BRCA1-targeting lentivirus were pretreated for 48 hours 
with 10 nM 17-AAG or DMSO control.  Cells were trypsinized, counted, and 3,000 cells were 
plated in 60 mm dishes with fresh 17-AAG or DMSO.  After resting overnight, plates were 
radiated with 0, 1, 2, 4, or 6 Gy and were then incubated for an additional 10 days.  Plates were 
fixed with 100% methanol, stained with 1% crystal violet, and colonies were imaged and 
counted using the UVP BioImaging System and ImageJ, respectively. 
 
MTS Assay 
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Cells were plated at 3x10
5
 (HCC1937 and UWB1.289) or 5x10
3
 (MCF7) cells per well in a 96-
well plate and were treated for 4 (MCF7) or 5 (HCC1937 and UWB1.289) days with indicated 
doses of 17-AAG or carboplatin.  Assay was performed using the CellTiter 96
® 
AQueous MTS kit 
(Promega) according to the manufacturer’s instructions. 
 
Cell Cycle, DNA Synthesis and Apoptosis Assays 
HCC1937 and HCC1937
BRCA1
 cells were treated with 250 nM 17-AAG or DMSO for indicated 
times.  For cell cycle analysis, cells were trypsinized and resuspended in 1 mL of 0.9% NaCl, 
and vortexed gently during dropwise addition of 2.5 mL 90% cold ethanol.  After 30 minutes of 
fixation on ice, cells were stained with 50 μg/mL propodium iodide and treated with RNase A for 
30 minutes at room temperature.  For studies examining mitotic entry, cell cycle staining was 
completed as described, with the addition of Alexa®-488 anti-pH3
S28
 (#558610, BD 
Biosciences) staining step per the manufacturer’s instructions.  DNA synthesis and TUNEL 
staining was performed using the Click-iT® EdU cell proliferation assay (Invitrogen) and the 
Click-iT TUNEL assay (Invitrogen) as described by the manufacturer.  Annexin staining assay 
was done with V450 Annexin V (BD Biosciences, #560506) per manufacturer supplied protocol.  
All experiments were analyzed on LSR II flow cytometer (BD Biosciences) except for the 
TUNEL assay which was analyzed on a Celigo adherent cell cytometer (Cyntellect).  
 
Results 
17-AAG Regulates the Stability of Both Wild-Type and Mutant Forms of BRCA1 
Because mutation-associated resistance to platinum-based chemotherapeutics and PARP 
inhibitors arises from intragenic alterations in mutant BRCA1/2 alleles, we assessed the ability of 
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17-AAG to destabilize mutant forms of BRCA1 protein in HCC1937 breast cancer cells 
(homozygous BRCA1 5382insC) and UWB1.289 ovarian cancer cells (homozygous BRCA1 
2594 del C) (Figure 1A).  17-AAG treatment resulted in downregulation of both BRCA1 mutants 
(Figure 1B), although to a less dramatic extent than in the BRCA1 wild-type cells examined 
previously (Chapter II Figures 1A-B and 6A).  To determine whether the kinetics of wild-type 
and mutant BRCA1 loss differed in isogenic cell lines, we evaluated the response of HCC1937 
cells as well as a wild-type BRCA1-complemented clone (designated HCC1937
BRCA1
) to 250 nM 
17-AAG for 0-5 days.  Wild-type and mutant BRCA1 were lost at similar rates, with a nadir of 
approximately 40% at day 3 in both cell lines (Figure 2A-B). 
 
BRCA1 Expression Regulates Sensitivity to 17-AAG and Mediates HSP90 Inhibitor-Induced 
Sensitivity to Ionizing Radiation 
Since BRCA1 is a central scaffolding protein for assembling the HR machinery, loss of BRCA1 
should eliminate synergy between 17-AAG and agents which induce HR-mediated repair.  To 
address this, we generated MCF7 cells with reduced expression of BRCA1 via lentiviral 
shRNAs.  Three populations of MCF7 cells were selected with variable levels of BRCA1 
expression, though HSP90 expression was unaffected (Figure 3A).  Given our previous finding 
that 17-AAG induces or augments γH2AX phosphorylation (i.e., enhances accumulation of 
DSBs) (Chapter II Figure 10), we hypothesized that BRCA1-deficient cells would be 
intrinsically sensitive to 17-AAG.  MCF7 cells with variable expression of BRCA1 were treated 
with increasing doses of 17-AAG for four days and subjected to MTS assay.  The ability to 
proliferate in the presence of 17-AAG closely parallels the level of BRCA1 expression (Figure 
3A-B).  The IC50 values of shRNA1, shRNA2, shRNA3 and control populations were 137 nM, 
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204 nM, 305 nM, and 832 nM, respectively (Figure 3C).  We confirmed this finding in the 
BRCA1 mutant breast cancer cell line HCC1937 and the BRCA1 wild-type complemented clone 
HCC1937
BRCA1
, where IC50 values were found to be 101 nM and 331 nM, respectively (Figure 
4A-B).  To address whether loss of BRCA1 is epistatic to the ability of 17-AAG to potentiate 
cells to ionizing radiation, the MCF7-shRNA2 and MCF7-control populations were treated with 
DMSO or 10 nM 17-AAG for two days and then were irradiated and assessed for clonogenic 
growth capacity (Figure 5A).  This low dose and shorter duration of 17-AAG was selected 
because it effectively ablates BRCA1 expression (Chapter II Figure 1A-B) and has insignificant 
effects on the proliferation of both control and BRCA1-ablated MCF7 cells (Figure 5B and 3B 
(arrow)).  17-AAG treatment significantly potentiated MCF7-control cells to clinically-relevant 
doses of IR (Figure 5C-D).  As expected, loss of BRCA1 alone also potentiated cells to IR 
(Figure 5C-D).  Unexpectedly, 17-AAG treatment of BRCA1-deficient MCF7 cells revealed no 
synergy between 17-AAG and IR (Figure 5C-D).  These data suggest that a major sensitizing 
effect of 17-AAG is due to loss of BRCA1.  Our finding that loss of BRCA1 prevents any further 
potentiation has important implications and may provide further functional support for a role of 
BRCA1 in NHEJ. 
 
17-AAG Exhibits Enhanced Synergy in Cells with Restored Wild-Type BRCA1 and can Re-
Sensitize Platinum-Resistant Breast and Ovarian Cancer Cells 
Overexpression of wild-type BRCA1 and frame-restoring intragenic mutations in BRCA1 are 
associated with resistance to platinum-based chemotherapeutics and PARP inhibitors in ovarian 
cancer.  To evaluate whether 17-AAG could mitigate repair-mediated resistance arising from 
BRCA1-dependent DNA damage repair, we evaluated the ability of 17-AAG to sensitize 
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BRCA1-mutant and wild-type complemented breast and ovarian cancer cells (HCC1937 and 
UWB1.289, respectively).  As expected, complementation of wild-type BRCA1 (HCC1937
BRCA1
 
and UWB1.289
BRCA1
) increased resistance to carboplatin in both models (Figure 6A-D).  
HCC1937, HCC1937
BRCA1
, UWB1.289 and UWB1.289
BRCA1 
cells were treated with 
combinations of 17-AAG and carboplatin and assessed by MTS assay to evaluate synergy.  Our 
studies of combinatorial drug effect were performed in CalcuSyn and are based on the reasoning 
detailed in Appendix A. 
 
17-AAG increased sensitivity to carboplatin in all cell lines (Figure 7A-C).  Viability data at all 
equal-ratio combinations (Figure 7A-B, dotted boxes) enabled mathematical quantification of 
synergy as a combination index (  ) based on Equation 15 (Appendix A).  17-AAG and 
carboplatin were highly synergistic in HCC1937 and HCC1937
BRCA1
 cells, though the interaction 
of the two drugs in both mutant and wild-type complemented UWB1.289 cells appeared to be 
only additive (Figures 8 and 9).  In the HCC1937 model, synergy was generally more 
pronounced in the wild-type complemented cell lines at the 100:1 and 1000:1 combination ratios 
(Figures 8 and 9).  We interpret our findings to mean that the additional synergy observed in the 
wild-type complemented cell HCC1937 line is due to abrogation of BRCA1-dependent repair of 
carboplatin interstrand crosslinks.  The lack of synergistic activity in the UWB1.289 cell model 
may be explained by a report indicating that complementation of wild-type BRCA1 in this cell 
line only partially corrects the DNA damage response (DelloRusso et al., 2007).  This is 
consistent with our data showing a modest and non-significant increase in resistance to 
carboplatin in the BRCA1 wild-type complemented UWB1.289 cell line (Figure 6C-D). 
 
111
A B
C D
HC
C1
93
7
BR
CA
1
HC
C1
03
7
0
20
40
60 *
µM
 C
ar
bo
pl
at
in
-6.0 -5.5 -5.0 -4.5 -4.0
0
25
50
75
100
125
HCC1937
HCC1937BRCA1
Log10 [Carboplatin] Molar
R
el
at
iv
e 
C
el
l N
um
be
r 
(%
)
-6.0 -5.5 -5.0 -4.5 -4.0
0
25
50
75
100
125
UWB1.289
UWB1.289BRCA1
Log10 [Carboplatin] Molar
R
el
at
iv
e 
C
el
l N
um
be
r 
(%
)
UW
B1
.28
9
BR
CA
1
UW
B1
.28
9
0
5
10
15
µM
 C
ar
bo
pl
at
in
112
113
A
B
C
114
115
A
B
10:1
100:1
1000:1
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
2
4
6
8
Fractional Effect
C
om
bi
na
ti
on
 In
de
x
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
2
4
6
8
Fractional Effect
C
om
bi
na
ti
on
 In
de
x
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
2
4
6
8
Fractional Effect
C
om
bi
na
ti
on
 In
de
x
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
2
4
6
8
Fractional Effect
C
om
bi
na
ti
on
 In
de
x
116
117
HCC1937
HCC1937BRCA1
-2
-1
0
1
2
Lo
g 1
0 
C
I
-2
-1
0
1
2
Lo
g 1
0 
C
I
IC50 IC75 IC90
-2
-1
0
1
2
Lo
g 1
0 
C
I
Fractional  Effect of Carboplatin
IC50 IC75 IC90
Fractional  Effect of Carboplatin
UWB1.289
UWB1.289BRCA1
-2
-1
0
1
2
Lo
g 1
0 
CI
-2
-1
0
1
2
Lo
g 1
0 
CI
-2
-1
0
1
2
Lo
g 1
0 
CI
10:1
100:1
*
1000:1
10:1
100:1
1000:1
* p=0.0867
p=0.0929
*
*p=0.0534
** **
A B
118
119
 
To evaluate the ability of 17-AAG to resensitize non-BRCA1-mutant ovarian cancer cells, we 
employed the A2780 cell line and two platinum-resistant clones of this line designated CP70 and 
C30.  The carboplatin IC50 in A2780 cells was noted to be 46 μM, while the CP70 and C30 cell 
lines had not reached IC50 by 100 μM (Figure 10A).  Sensitivity to 17-AAG was not significantly 
different between A2780 cells and either resistant clone, though the C30 clone did exhibit 
significant 17-AAG resistance compared to the CP70 clone (Figure 10B).  Consistent with our 
previous studies, treatment with 17-AAG abolished expression of BRCA1 and other described 
HSP90 client proteins involved in homologous recombination, including BRCA2, CHK1 and 
RAD51 (Figure 10C).  As before, combinatorial treatment of A2780, C70 and C30 cells with 
carboplatin and 17-AAG was performed to evaluate whether 17-AAG could resensitize 
platinum-resistant sporadic ovarian cancer cells.  In A2780 and C30 cells, combinatorial 
treatment with 17-AAG and carboplatin resulted in greater suppression of cell growth than did 
either agent alone, while in CP70 cells, the bulk of the therapeutic effect appeared to be due to 
the action of 17-AAG alone (Figure 11A-B).  Quantification of the CI did reveal synergy in all 
three cell lines at nearly all drug ratios and effect levels, though only the C30 clone exhibited 
enhanced synergy at the 100:1 and 1000:1 ratios when compared to the parental A2780 cell line 
(Figures 12 and 13). 
 
Wild-Type BRCA1 Prevents Mitotic Entry After HSP90 Inhibition 
In addition to coordinating the repair of DSBs, BRCA1 also regulates multiple aspects of cell 
cycle progression and induces the G2/M checkpoint to prevent perpetuation of genetic damage 
through mitosis.  We sought to examine whether BRCA1 status influenced activation of the 
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G2/M checkpoint and whether changes in DNA synthesis and/or drug-induced apoptosis were 
responsible for differential sensitivity of BRCA1 wild-type and mutant cell lines to 17-AAG. 
 
In both HCC1937 and HCC1937
BRCA1
 cells, treatment with 17-AAG induced a pronounced 
G2/M arrest at 24 hours (Figure 14A-B).  To discriminate whether cells were arresting in G2 or 
M phase, we performed cell cycle analysis with costaining for pH3
S28
, a histone modification 
only present during mitosis.  Upon treatment with 17-AAG, pH3
S28
 staining increased from 3.9% 
to 38.0% in the BRCA1 mutant HCC1937 cells, compared to a much more modest increase from 
3.0% to 7.9% in the wild-type complemented HCC1937
BRCA1
 cells (Figure 15A-B).  We further 
evaluated the effects of 17-AAG on mitotic progression in HCC1937 and HCC1937
BRCA1
 cells in 
the presence and absence of radiation-induced DNA damage.  Consistent with our flow 
cytometric findings, phosphorylation of H3
S10
, another mitosis-associated histone 
phosphorylation event, and expression of the M-phase specific cyclin B1 were only induced in 
BRCA1-mutant HCC1937 cells after 17-AAG treatment (Figure 16).  These data imply that wild-
type BRCA1 is able to prevent 17-AAG-induced entry into M phase, while cells harbouring 
mutant BRCA1 fail to activate the G2/M checkpoint and progress into mitosis despite the 
presence of DNA damage.  BRCA1 activates the G2/M checkpoint by facilitating the 
phosphorylation of CHK1
S345
, and in effect, by regulating the expression, phosphorylation and 
localization of CDC25C and the CDC2/cyclin B-complex (Yamane et al., 2007; Yarden et al., 
2002).  Because CHK1 is a known client protein of HSP90 (Arlander et al., 2003), we sought to 
understand whether 17-AAG induced G2/M arrest depended on the ability of BRCA1 to activate 
CHK1.  Consistent with previous reports, 17-AAG treatment of both cell lines destabilized 
CHK1 (Figure 16).  As expected, radiation-induced phosphorylation of CHK1
S345
 was much 
129
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more robust in HCC1937
BRCA1
 cells than in HCC1937 cells, and 17-AAG interfered with this 
phorphorylation event (Figure 16).  HCC1937
BRCA1
 cells did not induce H3
S10
 phorphorylation or 
cyclin B1 expression in response to 17-AAG in the presence or absence of radiation, implying 
that BRCA1 prevents 17-AAG induced mitotic entry independently of its well-characterized role 
in promoting CHK1
S345
 phosphorylation (Figure 16).  Interestingly, we did note that 17-AAG did 
not destabilize CHK1 to the same extent in HCC1937
BRCA1
 cells as it did in BRCA1 mutant 
HCC1937 cells (Figures 16 and 17). 
 
17-AAG Selectively Reduces Replication Capacity in BRCA1-Mutant Cells 
Cell cycle analysis also indicated that 17-AAG selectively reduced DNA synthesis in the BRCA1 
mutant HCC1937 cells (Figure 14A-B).  To confirm this, we performed EdU incorporation 
assays following 17-AAG treatment.  Loss of BRCA1 has been shown to accelerate growth in 
tumor cells (Thompson et al., 1995).  Consistent with these reports, HCC1937
BRCA1
 cells 
incorporated EdU more slowly than the mutant HCC1937 cells (Figures 18A-B).  Treatment with 
17-AAG reduced DNA synthesis by nearly 50% in the mutant HCC1937 cells, while having no 
discernible effect on the wild-type complemented HCC1937
BRCA1
 cells (Figures 18A-B).  The 
spontaneous accumulation of DSBs in response to 17-AAG (Chapter II Figure 10) will incite 
replication stress during S phase.  Our data suggest that BRCA1 mutant cells will acutely lose 
replication capacity in response to 17-AAG, as they are unable to resolve stalled replication 
structures, while those cells with wild-type BRCA1 may be resistant to 17-AAG-induced 
replication stress, at least initially. 
 
Loss of BRCA1 Enhances 17-AAG-Induced Apoptosis 
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Though we observed dramatic BRCA1-dependent changes in mitotic progression and DNA 
synthesis in response to 17-AAG, we sought to understand the contribution of cell death to the 
hypersensitivity phenotype observed in BRCA1-mutant HCC1937 cells.  Annexin V staining (a 
marker of early apoptosis) was performed at 24 hours after 17-AAG treatment and TUNEL 
staining (a marker of late apoptosis) at 24, 48 and 72 hours post treatment.  Annexin V staining 
increased from 2.0% to 28.4% after 24 hours of 17-AAG treatment in HCC1937 cells, compared 
to an increase from 2.0% to 6.4% in HCC1937
BRCA1
 cells (Figures 19A-B).  No difference in 
TUNEL staining was evident at 24 or 48 hours, but by 72 hours, the HCC1937 cells exhibited 
significantly more DNA fragmentation than the wild-type HCC1937
BRCA1
 cells (Figures 20A-B).   
 
Treatment with N-terminal HSP90 inhibitors, like 17-AAG, disrupt the interaction between 
HSP90 and heat shock factor 1 (HSF1), and induce expression of stress responsive genes like 
HSP70 (Creagh et al., 2000; Morimoto, 1998; Zou et al., 1998).  The inability to mount such a 
stress response has previously been associated with hypersensitivity to HSP90 inhibitors 
(Bagatell et al., 2000).  To evaluate whether BRCA1 expression altered the heat shock response, 
HCC1937 and HCC1937
BRCA1
 cells were exposed to heat shock (42°C).  In response to 
proteomic stress, HSF1 becomes phosphorylated by a number of kinases and induces expression 
of multiple genes involved in protection from thermal and other stresses (Holmberg et al., 2001).  
In both HCC1937 and HCC1937
BRCA1
 cells, the electrophoretic mobility of HSF1 shifted in a 
similar manner, and there were no observed differences in expression of the critical heat shock 
protein HSP70 (Figure 21).  Conversely, it was noted that HSP27, a heat shock protein with 
significant anti-apoptotic activity was overexpressed in HCC1937
BRCA1
 cells, even in the absence 
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of heat shock (Figure 21), suggesting that functional BRCA1 may mitigate proteomic stress and 
prevent heat shock-induced apoptosis. 
 
Discussion 
In this chapter, we characterized the role of BRCA1 in regulating 17-AAG-induced cytotoxicity 
of ionizing radiation and carboplatin, and also evaluated the role of BRCA1 mutational status in 
mediating acute cell cycle, replication and apoptotic responses to 17-AAG treatment.  As 
detailed in the previous chapter, 17-AAG treatment abolished BRCA1 expression and almost 
completely inhibited homologous and non-homologous repair of DSBs.  Though BRCA1 is 
known to be critical for HR, limited data supports a direct role for BRCA1 in NHEJ, though this 
function remains poorly described and is complicated by conflicting reports suggesting that 
BRCA1 mutant cancer cells may rejoin DSBs efficiently (Bau et al., 2004; Merel et al., 2002; 
Wei et al., 2008a; Zhuang et al., 2006).  Our finding that BRCA1 deficiency prevented 17-AAG 
from further sensitizing cells to IR is intriguing, since NHEJ is thought to repair the bulk of 
DSBs induced by IR.  From these data, we speculate that the radiopotentiating effect of HSP90 
inhibitors is due to inhibiting HR alone or that BRCA1 indeed participates in NHEJ. 
 
One report has suggested that BRCA1 is critical for inducing the G2/M checkpoint in breast 
cancer cells following treatment with 17-AAG (Zajac et al., 2008).  Our data further define the 
response of both BRCA1-mutant and wild-type cells to HSP90 inhibition.  Specifically, we show 
that without functional BRCA1, cells experience acute replication stress and progress into mitosis 
despite the presence of DNA damage.  Our data presented in the current and previous chapters 
strongly suggest that 17-AAG induces loss of BRCA1 expression.  We thus modify the 
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interpretation offered in the aforementioned report and speculate that expression of functional 
BRCA1 merely delays aberrant mitosis and temporarily mitigates replication stress, and that 
following 17-AAG-induced BRCA1 degradation, cells with wild-type BRCA1 will ultimately 
succumb to the same fate.  In direct conflict with our data, this same report indicated no 
differential sensitivity of BRCA1-wild-type and -null cells to 17-AAG.  Their study examined the 
sensitivity of numerous breast cancer cell lines based on BRCA1 status alone, and did not 
account for the numerous physiological and genetic differences that can exist between different 
cell lines.  Our examination of sensitivity in a two syngeneic systems with differential expression 
of BRCA1 revealed a strong correlation between BRCA1 expression and sensitivity to 17-AAG.  
Our finding that 17-AAG alone induced γH2AX foci formation (and thus accumulation of DSBs) 
(Chapter II Figure 10) would predict that BRCA1-deficient cells would exhibit increased 
sensitivity, and our evidence of enhanced synergy between carboplatin and 17-AAG in these 
cellular models provides further support for this interaction. 
 
Finally, our results suggest that acute inhibition of HSP90 may selectively induce BRCA1-mutant 
or BRCA1-deficient cells to experience replicative stress and/or to enter into aberrant mitosis.  
BRCA1 expression is strongly induced at the G1/S transition and remains highly expressed 
through the G2 phase (Blackshear et al., 1998; Chen et al., 1996; Gudas et al., 1996; Rajan et al., 
1996; Vaughn et al., 1996).  During S phase, BRCA1 localizes to sites of stalled or collapsed 
replication forks where it interacts with CtIP and the MRE11/RAD50/NBS1 complex to facilitate 
end resection and lesion bypass through sister chromatid exchange (Scully et al., 1997; Yu et al., 
1998).  In the absence of functional BRCA1, HR-mediated bypass of stalled replication forks 
cannot be accomplished, and thus BRCA1-deficient cells rely heavily on ancillary repair 
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pathways.  An interesting and clinically relevant association has been noted between 
poly(ADP)ribose polymerase (PARP) enzymes and maintenance of replicative potential in 
BRCA1- and BRCA2-mutant cells.  PARPs are best characterized for their role in base excision 
repair (BER) of ssDNA breaks, and are required for efficient recruitment of XRCC1 and 
processing of ssDNA lesions (El-Khamisy et al., 2003; Masson et al., 1998; Sanderson and 
Lindahl, 2002; Woodhouse et al., 2008).  Deficiency of HR (e.g., BRCA1/2 mutation) renders 
cells exquisitely sensitive to inhibition of PARP (Farmer et al., 2005; Fong et al., 2009; Fong et 
al., 2010), and conversely, genetic deficiency of PARP1 leads to increased frequency of sister 
chromatid exchange and repair of stalled replication structures by homologous recombination 
(Oikawa et al., 1980; Simbulan-Rosenthal et al., 1999; Wang et al., 1997).  Our finding that 17-
AAG selectively reduces replication potential in BRCA1-mutant HCC1937 cells suggests that 
one or more client proteins of HSP90 may have a synthetic lethal relationship with BRCA1.  We 
assume that PARP is not this candidate molecule, as 17-AAG has been demonstrated to be 
synergistic with PARP inhibiton in glioma cells and treatment with several HSP90 inhibitors 
induces PARP cleavage (a measure of imminent apoptosis) (Dungey et al., 2009; Khong and 
Spencer, 2011; Kim et al., 2012; Liu et al., 2011). 
 
As modeled in Figure 22, we propose a model whereby 17-AAG induces accumulation of 
sporadic DSBs.  Cells with functional BRCA1 are able to activate CHK1 in an ATR-dependent 
manner (Yarden et al., 2002), leading to phosphorylation and degradation of the CDC25A and 
CDC25C phosphatases (Wagner and Kaufmann, 2010).  This in turn leads to S and G2 phase 
arrest, allowing BRCA1 to facilitate homologous recombination and resolution of spontaneous 
DSBs.  In cells with mutant BRCA1, ATR is unable to phosphorylate CHK1, leading to 
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accumulation of unphosphorylated CDC25A and CDC25C which will activate the CDK2/Cyclin 
A/E (S phase) and CDK1/Cyclin B (M phase) cell cycle machinery, respectively.  The absence 
of HR in BRCA1 mutant cells will also lead to persistence of DSBs, which will trigger 
replication stress in cells in S phase and ultimately lead to mitotic catastrophe in cells which 
enter mitosis. 
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Chapter IV:  BRCA1 Promoter Methylation as a Predictive Biomarker for Response to 
Adjuvant Anthracycline Therapy in Triple-Negative Breast Cancer 
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Introduction 
Triple-negative (TN) breast cancers (TNBCs) account for approximately 15% of all invasive 
breast cancers and are typically of high histological grade, demonstrate high mitotic indices, 
mutations in the TP53 tumor suppressor gene, and are defined immunohistochemically as those 
lesions which lack expression of estrogen receptor (ER), progesterone receptor (PR) and HER2.  
Due to the absence of these receptors, TNBCs are not amenable to the targeted anti-estrogen and 
anti-HER2 therapies that have dramatically improved survival of patients diagnosed with 
luminal-type or HER2-positive tumors.  Modern pathologic diagnosis continues to rely heavily 
on expression of ER, PR and HER2, while most breast cancers will not be subjected to molecular 
taxonomic analysis.  Despite the limited use of molecular analysis clinically, several studies have 
demonstrated that immunohistochemically-defined TNBCs are highly represented in the basal-
like breast cancer (BLBC) molecular subtype.  Despite the notable similarities between TNBCs 
and BLBCs, caution should be exercised in equating these classification schemes as numerous 
studies have demonstrated that not all TNBCs exhibit basal-like transcriptional signatures and 
not all BLBCs are of the TN immunophenotype (Bertucci et al., 2008; Calza et al., 2006; Cheang 
et al., 2008; de Ronde et al., 2010; Jumppanen et al., 2007; Nielsen et al., 2004; Rakha et al., 
2008a; Rakha and Reis-Filho, 2009; Rakha et al., 2007a; Rakha et al., 2009; Rakha and Ellis, 
2009; Rakha et al., 2008b, c; Rakha et al., 2007b; Rouzier et al., 2005; Weigelt et al., 2010). 
 
Loss of normal BRCA1 expression and function has been noted to be among the most common 
recurrent molecular abnormalities noted in BLBCs.  Indeed, tumors arising in BRCA1 mutation 
carriers are overwhelmingly triple-negative and exhibit a basal-like transcriptional signature 
(Lim et al., 2009; Turner and Reis-Filho, 2006).  Moreover, sporadic BLBCs commonly 
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demonstrate downregulated BRCA1 expression in the absence of mutations at the BRCA1 locus, 
a phenotype that has been termed “BRCAness” (Thompson et al., 1995; Turner et al., 2004; 
Turner et al., 2007).  As has been discussed extensively in previous chapters, disruption of 
BRCA1 (or BRCA2) function by genetic or epigenetic mechanisms results in compromised 
capacity to repair double-strand DNA breaks (DSBs) and interstrand crosslinks (ICLs) by 
homologous recombination (HR) (Jasin, 2002).  While this genomic instability likely underlies 
the proclivity for tumorigenesis observed in heterozygous individuals, it also may lend to 
therapeutic exploitation.  Agents that induce DSBs (i.e., ionizing radiation and bleomycin) or 
ICLs (i.e., platinum-based alyklating agents) appear to be significantly more toxic in cells with 
reduced or absent expression of BRCA1 (Abbott et al., 1999; Bhattacharyya et al., 2000; Husain 
et al., 1998; Quinn et al., 2003).  Accordingly, human breast cancers arising in BRCA1 mutation 
carriers are more likely to achieve clinical responses in response to platinum-based agents than 
non-BRCA1/2 tumors (Isakoff, 2010).  Conversely, because of the critical role of BRCA1 in 
inducing G2/M arrest in response to microtubule poisons, tumors deficient in BRCA1 tend to be 
relatively resistant to these agents (Lafarge et al., 2001; Mullan et al., 2001; Quinn et al., 2003; 
Tassone et al., 2005).  Thus, selection of specific cytotoxic agents based on DSB repair capacity 
may improve responses to traditional chemotherapeutic agents and enable personalized cytotoxic 
chemotherapy (Price and Monteiro, 2010). 
 
Current first-line treatment for breast cancer is usually anthracycline-based, regardless of 
immunohistochemical or molecular subtype.  While anthracyclines have shown significant 
activity in breast cancer patients as a collective group, meaningful clinical outcomes in the 
BLBC subgroup continue to lag behind those that have been achieved in the ER/PR+ and 
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HER2+ groups.  Given the prevalence of BRCA1 dysfunction in TNBCs, it is rational to 
speculate that agents that induce DSBs or ICLs and require the homologous recombination 
pathway to be resolved may be more efficacious in treating these lesions.  While anthracyclines 
are known to induce DSBs through inhibition of the re-ligation step of topoisomerase II (Tewey 
et al., 1984), repair of these lesions does not necessarily require the FA/BRCA pathway, as most 
DSBs in higher eukaryotes are repaired via non-homologous end joining (NHEJ) (Shrivastav et 
al., 2008).  Since productive resolution of an ICL requires the FA/BRCA pathway, agents which 
induce ICLs may be especially useful in TNBC treatment. 
 
In this chapter, we retrospectively evaluated whether methylation of a particular CpG island in 
the BRCA1 promoter in 39 triple-negative breast cancer patients could predict relapse-free 
survival (RFS) or overall survival (OS) after adjuvant anthracycline therapy.  Methylation of this 
region of the BRCA1 gene has been shown in numerous series to be associated with reduced 
BRCA1 mRNA and/or protein expression (Matros et al., 2005; Scardocci et al., 2006; Wang et 
al., 2010; Wei et al., 2005).  Our data from this this small cohort suggests that methylation of this 
specific CpG island correlates with reduced BRCA1 mRNA expression and poor RFS and OS in 
anthracycline-treated patients.  We are currently evaluating whether this same biomarker can 
predict response to neoadjuvant carboplatin in a prospective cohort of TNBC patients. 
 
Clinical Samples and Materials and Methods 
Patient Identification 
Subjects with early stage (stage I-III) TNBC treated with adjuvant/neoadjuvant chemotherapy 
between 1996- 2008 at the University of Kansas Medical Center were identified under an IRB 
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approved protocol and their formalin-fixed paraffin-embedded (FFPE) breast tumor specimens 
were retrieved from pathology archives.  
 
DNA and RNA Isolation 
Tumor-dense (>75%) areas were dissected from paraffin curls (20 μm).  Genomic DNA (gDNA) 
was isolated using the QIAamp FFPE Kit (Qiagen) and total RNA was isolated using the 
RecoverAll® Kit (Ambion/Life Technologies). 
 
 
Bisulfite Conversion and Methylation-Specific PCR 
Tumor-derived gDNA was bisulfite converted using the EpiTect® Plus FFPE Bisulfite Kit 
(Qiagen, Valencia, CA).  Purified converted DNA was subjected to methylation-specific PCR 
(MSP) using the EpiTect® MSP Kit.  The locus being analyzed (Figure 1) and primer sets have 
been previously validated (Esteller et al., 2000; Matros et al., 2005; Scardocci et al., 2006; Wang 
et al., 2010; Wei et al., 2005): 
BRCA1 Unmethylated Forward 5’ – TTGGTTTTTGTGGTAATGGAAAAGTGT – 3’  
BRCA1 Unmethylated Reverse 5’ – CAAAAAATCTCAACAAACTCACACCA – 3’  
BRCA1 Methylated Forward 5’ – TCGTGGTAACGGAAAAGCGC – 3’ 
BRCA1 Methylated Reverse 5’ – AAATCTCAACGAACTCACGCCG – 3’ 
 
All primers were diluted to approximately 300 nM and all reactions used Tm = 55°C.  Specificity 
of reactions was confirmed using EpiTect® Universal Bisulfite-Converted DNA (Qiagen).  
Amplified samples were electrophoresed on a 2.5% agarose gel, stained with ethidium bromide, 
and visualized on a UVP Bioimaging System (UVP). 
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Quantitative Real-Time PCR 
Tumor-derived RNA was converted to cDNA and subjected to TaqMan® RT-PCR using probes 
specific for BRCA1 (Hs00173233_m1) and cyclophilin A (Hs99999904_m1) (Applied 
Biosystems/Life Technologies).  Each sample was assayed in duplicate for both targets on an 
ABI 7500 RT-PCR thermal cycler (Applied Biosystems/Life Technologies).  BRCA1 transcript 
levels were normalized to cyclophilin A using the ΔΔCt method (Livak and Schmittgen, 2001). 
 
Statistics 
Relapse free survival (RFS) and overall survival (OS) were estimated according to the Kaplan-
Meier method and compared among groups with log-rank statistic. Cox proportional hazards 
models were fit to determine the association of BRCA1 promoter methylation with the risk of 
recurrence and death after adjustment for other characteristics.  
 
Results 
Assay Performance and Subject Demographics 
Archived tumor tissue was identified for 39 subjects.  BRCA1 promoter methylation-specific 
PCR (MSP) was successful in 37/39 (95%) of specimens and BRCA1 mRNA qRT-PCR was 
successful in 35/39 (90%) of specimens.  Table 1 summarizes the demographics of the 37 
patients for whom MSP analysis was successful.  Consistent with current clinical practice, the 
majority (90%) of these patients had received an anthracycline as first-line chemotherapy (Table 
I). 
 
BRCA1 Promoter Methylation, mRNA Expression and Clinical Outcomes 
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Of the 37 tumors in which the MSP assay was successful, 11 (30%) exhibited BRCA1 promoter 
methylation (Figure 2A-B).  Methylation of the BRCA1 gene was significantly associated with 
downregulation of BRCA1 mRNA expression (Figure 3), but we did not uncover any significant 
association with age, nodal status or T stage.  At a median follow-up of six years (8-148 months), 
there have been 19 (51%) recurrences and 14 (37%) deaths.  On univariate analysis, node 
positivity, higher stage and presence of BRCA1 promoter methylation were associated with 
poorer RFS and OS (Figure 4A-B).  Five-year RFS and OS was 27% and 36%, respectively, for 
patients with methylation of the BRCA1 promoter compared to 61% and 81%, respectively, for 
patients whose tumors did not exhibit BRCA1 promoter methylation.  After adjustment for stage 
and nodal status, patients with BRCA1 promoter methylation still exhibited poorer OS compared 
to patients without methylation (HR=3.0, 95% CI: 1.1-8.0, p=0.002). 
 
Discussion 
Numerous studies have evaluated clinical outcomes in BRCA1-associated breast cancer, and a 
recent large meta-analysis argues that the prognosis of both BRCA1- and BRCA2-associated 
breast cancers is similar to that of sporadic breast cancers (Bordeleau et al., 2010).  This is in 
stark contrast to a large body of evidence suggesting that BRCA1- and BRCA2-associated 
epithelial ovarian cancer carries an improved prognosis when compared to sporadic cancers 
(Bolton et al., 2012).  As was discussed in Chapter I, platinum-based chemotherapeutic agents 
have been a mainstay of treatment for epithelial ovarian cancer for decades, while first-line use 
of these agents in breast cancer is uncommon.  BRCA1/2-mutant cells should exhibit intrinsic 
sensitivity to platinum-based agents, as resolution of platinum-induced damage requires 
homology-directed repair of interstrand crosslinks.  It is thus interesting to speculate that use of 
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platinum agents in BRCA1/2-associated breast cancers may render a similar trend to that seen in 
ovarian cancer. 
 
In sporadic ovarian cancers, deficiency of BRCA1/2 expression or function (i.e., “BRCAness”) 
has also been associated with improved responses and/or prolonged survival to platinum-based 
chemotherapy (Konstantinopoulos et al., 2010; Quinn et al., 2007; Swisher et al., 2009; 
Taniguchi et al., 2003; Teodoridis et al., 2005; Weberpals et al., 2009).  In sporadic breast 
cancers, it has been noted by several studies that methylation of BRCA1 may be associated with 
poor clinical outcome (Chen et al., 2009; Sharma et al., 2009; Xu et al., 2009; Xu et al., 2010).  
Again, we speculate that the absence of a survival benefit in sporadic breast cancers with 
BRCAness may be attributable to the omission of a platinum-based chemotherapeutic agent in 
the first-line treatment of these neoplasms.  This is supported by a recent study which used a 
comparative genomic hybridization (CGH) signature derived from BRCA1-mutant breast cancers 
to define sporadic HER2-negative tumors as BRCA1-like or non-BRCA1-like.  This report noted 
that patients with the BRCA1-like CGH profile experienced improved response and clinical 
outcomes on high-dose platinum-based chemotherapy compared to standard anthracycline-based 
chemotherapy (Vollebergh et al., 2011).  Similar results were obtained in a study of a multiplex 
methylation-based BRCAness profile in which high-dose alkylative chemotherapy including 
carboplatin led to improved survival in patients with a BRCAness profile (Lips et al., 2011). 
 
Our study defines BRCA1 promoter methylation as an adverse prognostic biomarker for 
anthracycline-treated TNBC.  These data, taken with the immense body of evidence supporting 
the use of platinum-based agents in ovarian cancer, suggest that use of platinum in TNBCs with 
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documented BRCA1/2-mutation or somatic loss of BRCA1 expression or function may improve 
clinical outcomes.  In addition to the potential improvement in anti-neoplastic activity, avoidance 
of anthracyclines in patients with germline BRCA1/2 mutation may be clinically important in its 
own rite, as myocardium-specific knockout of Brca1 or Brca2 in mice exaggerated cardiac 
dysfunction after myocardial infarct and, importantly, increased anthracycline-induced cardiac 
toxicity (Shukla et al., 2011; Singh et al., 2012).  Whether this hypersensitivity exists in the 
haploinsufficient myocardium of BRCA1 and BRCA2 patients remains to be studied.  In addition 
to the small number of samples evaluated, a major limitation of our study is that we were unable 
to ascertain BRCA1/2 mutation status, as only fixed paraffin-embedded tissue was available for 
analysis.  Despite this shortcoming, we can infer that all of the BRCA1-methylated tumors were 
from patients with wild-type BRCA1/2, as genetic and epigenetic inactivation of BRCA1 is 
virtually mutually exclusive in both breast and ovarian cancer (TCGA, 2011; Vollebergh et al., 
2011; Yang et al., 2011). 
 
We are currently examining BRCA1 promoter methylation prospectively in a cohort of 30 
neoadjuvant platinum-treated TNBC patients, all of whom have undergone comprehensive 
BRCA1 and BRCA2 germline mutation testing.  We expect that this study will illuminate BRCA1 
as a critical determinant of platinum sensitivity in TNBC and will lead to a pilot trial in which 
patients receive tailored cytotoxic chemotherapy based on BRCA1-dependent DNA damage 
repair capacity. 
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Chapter V:  Perspective and Conclusions 
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Intrinsic and acquired therapeutic resistance remains a tremendous clinical obstacle in the 
treatment of both breast and ovarian cancer.  A comprehensive understanding of the mechanisms 
which underlie therapeutic failure, coupled with advances in genetic and pharmacologic 
interventions which can combat resistance are certain to improve clinical outcomes for breast 
and ovarian cancer patients. 
 
BRCA1-Dependent DNA Damage Responses and Efficacy of Chemo- and Radiotherapy 
Breast cancer patients with no evidence of metastatic disease (i.e., stages I-III) are treated locally 
with curative intent by surgical excision and adjuvant radiotherapy.  Though such early stage 
disease is defined by the absence of overt metastatic involvement, the existence of 
micrometastatic deposits is likely in many of these patients.  To avoid recurrence from and 
progression of micrometastases, adjuvant systemic treatments including chemotherapy, 
endocrine therapies and biologic agents are utilized in an attempt to eradicate disease that was 
not surgically excised or biologically sterilized with radiotherapy.  In patients with more 
advanced, but still potentially curable disease (e.g., stage IIIB and operable stage IIIC), such 
systemic therapies may be used in the neoadjuvant setting to reduce tumor burden followed by 
surgery and radiotherapy. 
 
Treatment with ionizing radiation (IR) is an integral component of breast cancer therapy for 
patients with both early stage and advanced disease.  Nearly all patients who undergo breast 
conserving surgery (i.e., lumpectomy) for invasive and in situ disease will receive radiation, as 
will many patients undergoing mastectomy (Carlson and McCormick, 2005; Recht et al., 2001).  
In both cohorts, the addition of IR has been shown to dramatically reduce local recurrence, 
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which has been independently associated with improving overall survival (Clarke et al., 2005; 
Gebski et al., 2006).  In patients with advanced and metastatic disease, radiation is indispensable 
in slowing progression and providing palliation (Rades et al., 2006; van der Linden et al., 2005; 
Wadasadawala et al., 2007).  The lethal effects of IR are due to production of unrepairable DNA 
lesions involving DNA double-strand breaks (DSBs), and repair of DSBs is a major mechanism 
by which normal and cancer cells become resistant to IR.   
 
It has been noted that radiation produces fewer γH2AX foci (the hallmark of DSB induction) in a 
therapy-resistant population of quiescent breast cancer cells commonly known as cancer stem 
cells (CSCs), and that such foci resolved faster (i.e., were repaired more efficiently) in CSCs 
than in non-CSC populations (Diehn and Clarke, 2006; Phillips et al., 2006; Woodward et al., 
2007).  Non-homologous end joining (NHEJ), a relatively error-prone process that directly 
ligates strands following a break, is responsible for the bulk of DSB repair following irradiation, 
while the error-free homologous recombination (HR) pathway, involving BRCA1, BRCA2 and 
RAD51, plays a modest role in repair of IR-induced lesions.  Interestingly, it has been noted 
from in vitro studies of human breast cancer cell lines that HR, and not NHEJ, appears to be 
hyperactive in breast CSCs and may be responsible for the intrinsic radiation resistance of these 
cells (Yin and Glass, 2011).  As is the case for radiotherapy, heightened BRCA1-dependent 
DNA damage responses after neoadjuvant chemotherapy have been noted to predict poorer 
therapeutic response in breast cancer patients (Asakawa et al., 2010; Graeser et al., 2010).  Thus, 
targeting BRCA1-dependent DNA damage repair may represent a plausible mechanism to 
overcome radiation and chemotherapeutic resistance in breast cancer. 
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For ovarian cancer, cytoreductive “debulking” surgery followed by platinum-based 
chemotherapy remains the mainstay of first-line treatment (Schwartz, 2008; Wakabayashi et al., 
2008).  Because epithelial ovarian cancers are most commonly diagnosed at advanced stages (III 
or IV), most patients relapse and succumb to progressive disease despite extensive cytoreduction 
and often complete clinical responses to adjuvant chemotherapy (Miller and Rustin, 2010).  A 
major determinant of clinical outcome following relapse is the platinum-free interval (PFI), with 
women experiencing a recurrence within the first six months after completion of primary therapy 
defined as platinum-resistant, and women who experience a recurrence after six months being 
termed platninum-sensitive.  The former group of patients is treated in the second-line setting 
with non-cross-resistant agents, commonly including pegylated liposomal doxorubicin (PLD) 
while those who experience a remission lasting longer than six months may benefit from 
additional cycles of platinum-containing chemotherapy (Cantu et al., 2002; Monk and Coleman, 
2009; Pujade-Lauraine and Alexandre, 2011).  These studies argue that preserving or extending 
platinum-sensitivity in both primary and recurrent epithelial ovarian cancers are likely to 
improve survival. 
 
Recurrent ovarian cancers exhibit dramatically enhanced interstrand crosslink repair capacity 
(Wynne et al., 2007), suggesting that hyperactivity of BRCA1-dependent DNA damage repair is 
a significant contributor to therapeutic resistance in this setting.  This is supported by reports that 
high expression of BRCA1 or frame-restoring mutations in recurrent BRCA1-associated ovarian 
cancers is associated with platinum resistance and poor clinical outcome (Konstantinopoulos et 
al., 2010; Quinn et al., 2007; Swisher et al., 2009; Swisher et al., 2008; Teodoridis et al., 2005; 
Weberpals et al., 2009). 
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The purpose of this study was to evaluate the potential use of the clinically-relevant HSP90 
inhibitor 17-AAG in preventing BRCA1-dependent DNA damage repair, and to uncover the link 
between epigenetic silencing of BRCA1 and response to anthracycline chemotherapy in triple-
negative breast cancer.  During the course of these studies, we have identified a novel biological 
interaction between BRCA1 and HSP90 and demonstrate in vitro that 17-AAG can destabilize 
BRCA1, and in effect, abolish BRCA1-dependent DNA damage repair.  Importantly, we also 
demonstrate that 17-AAG is able to resensitize both sporadic and hereditary breast and ovarian 
cancer cell lines to ionizing radiation and/or platinum in a BRCA1-dependent manner.  These 
findings may have significant implications for treating platinum-resistant or -refractory ovarian 
cancer, and further argue that platinum-containing regimens may be superior to anthracycline 
therapy for a significant proportion of triple-negative breast cancer patients. 
 
Chapter II:  BRCA1 Stability and Function is Regulated by HSP90 
HSP90 inhibitors are known to increase sensitivity to numerous genotoxic agents, including 
radiation and platinum-based crosslinking agents (Arlander et al., 2003; Bagatell et al., 2005; 
Camphausen and Tofilon, 2007; Dote et al., 2006; Georgakis et al., 2006; Munster et al., 2001; 
Yao et al., 2007).  Despite this observation, the mechanism(s) by which these agents enhance 
therapeutic efficacy remain incompletely understood.  The aim of this study was to evaluate 
whether HSP90 inhibitors influenced the expression and/or function of BRCA1, a critical 
determinant of DSB and ICL repair capacity.  We demonstrate that the clinically-relevant HSP90 
inhibitor 17-AAG induces polyubiquitination and proteasome-mediated degradation of BRCA1 
in numerous cancer cell lines and in effect, abolishes localization of BRCA1 to sites of DNA 
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damage.  We also functionally document dramatic reduction in repair of DSBs by both 
homologous recombination and non-homologous end joining after 17-AAG treatment.  Other 
components involved in the repair of DSBs and ICLs by homologous recombination are known 
clients of HSP90, including FANCA, CHK1 and BRCA2 (Arlander et al., 2003; Noguchi et al., 
2006; Oda et al., 2007).  Despite these known connections, BRCA1 occupies an apical position 
in the HR pathway and is epistatic to the function of all three of these proteins (Bhattacharyya et 
al., 2000; Folias et al., 2002; Yarden et al., 2002; Zhang et al., 2009).  Our data thus suggest that 
17-AAG-induced loss of BRCA1 is a key upstream event leading to DSB repair failure. 
 
Chapter III:  BRCA1 Regulates 17-AAG-Induced Radio- and Chemosensitization, G2/M 
Checkpoint Activation, Replication Stress Response and Apoptosis 
In addition to coordinating the repair of DSBs and ICLs, BRCA1 also plays critical roles in 
activating cell cycle checkpoints after genotoxic stress, maintaining the integrity of replication 
forks and regulating damage-associated apoptosis (Powell and Kachnic, 2003; Quinn et al., 
2003; Scully et al., 1997; Thangaraju et al., 2000; Tibbetts et al., 2000; Yarden et al., 2002).  
Given our finding that 17-AAG can regulate BRCA1 expression and function, the studies in this 
chapter were designed to evaluate whether 17-AAG differentially affected sensitivity to 
cytotoxic agents or influenced acute cell cycle, DNA replication and apoptotic responses in cells 
expressing mutant or wild-type BRCA1.  Towards this end, we demonstrated that BRCA1-
deficient and BRCA1-mutant breast cancer cells are hypersensitive to 17-AAG, and that 17-AAG 
was unable to hypersensitize BRCA1-deficient cells to ionizing radiation.  These findings are 
consistent with our assertion that 17-AAG-induced BRCA1 degradation is an important mediator 
of therapeutic hypersensitivity after HSP90 inhibition.  Furthermore, we show that 17-AAG can 
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sensitize BRCA1-mutant and sporadic breast and ovarian cancer cells to carboplatin, and that 
carboplatin resistance imbued by complementation of wild-type BRCA1 can be abolished by 17-
AAG treatment.  Our data also show that BRCA1-mutant breast cancer cells enter into 
catastrophic mitosis, acutely lose replication capacity, and undergo apoptosis following 17-AAG 
treatment, while an isogenic cell line complemented with wild-type BRCA1 is able to arrest in 
G2, maintain DNA synthesis and delay apoptosis.  Collectively, these data suggest that 17-AAG 
may be useful in treating breast and ovarian cancers which lack functional BRCA1 by two 
discrete mechanisms.  First, since 17-AAG causes the accumulation of spontaneous DSBs, cells 
which lack BRCA1 should be intrinsically hypersensitive to 17-AAG.  Second, and perhaps 
more importantly, 17-AAG can destabilize mutant and wild-type BRCA1, and should therefore 
be effective in preventing and reversing BRCA1-dependent DSB/ICL repair-mediated resistance.  
Since augmented DNA repair appears to be a significant contributor to radiation and platinum 
resistance, we speculate that HSP90 inhibitors may find success in treating resistant or refractory 
breast and ovarian cancer. 
 
Chapter IV:  BRCA1 Promoter Methylation as a Predictive Biomarker for Response to Adjuvant 
Anthracycline Therapy in Triple-Negative Breast Cancer 
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer, and effective 
treatment of TNBC is complicated by the paucity of targeted therapies.  Recent insights into the 
molecular pathogenesis of TNBCs have revealed that defects in homologous recombination, 
especially associated with the BRCA1 gene, are common and may be causally associated with the 
pathogenesis of these lesions.  Numerous studies have shown that ovarian cancers with inherited 
or acquired defects in BRCA1 expression or function may enjoy improved responses and/or 
179
 
clinical outcomes after platinum-based adjuvant cytotoxic therapy.  Similar trends have not 
emerged in breast cancer.  Platinum-based chemotherapeutic agents induce ICLs, a DNA lesion 
that requires BRCA1 to be functionally resolved.  It is thus not unexpected that BRCA1-deficient 
tumors should exhibit hypersensitivity to platinum, and repair-failure of platinum-induced 
lesions in BRCA1-deficient ovarian cancer almost certainly underlies the improved responses in 
these lesions.  It is thus interesting to speculate that improved survival in BRCA1-deficient 
breast cancer has not emerged because anthracyclines, rather than platinum, are used in the first-
line treatment of most breast cancer patients.  We sought to understand whether methylation of 
the BRCA1 promoter could predict responses to adjuvant anthracycline-based chemotherapy in a 
cohort of 39 TNBC patients.  Methylation of BRCA1 was associated with reduced expression of 
BRCA1 mRNA, and significantly poorer relapse-free and overall survival, even after adjustment 
for stage, nodal status.  This finding is not unexpected, as tumor cells lacking BRCA1 have 
enhanced proliferation rates and may be more invasive (Coene et al., 2011; Thompson et al., 
1995; Wang et al., 2008; Yasmeen et al., 2008).  Based on our work and the work of others, we 
argue that platinum-based chemotherapeutic agents should exploit an intrinsic vulnerability of 
BRCA1-deficient TNBCs and that ascertainment of ICL repair capacity, and subsequent tailoring 
of cytotoxic chemotherapy may improve clinical outcomes and survival in TNBC.  To address 
this issue, we are currently examining BRCA1 promoter methylation in a prospective cohort of 
TNBC patients treated with neoadjuvant carboplatin. 
 
Perspective 
Genetic and/or epigenetic inactivation of the FA/BRCA pathway, whether inherited or acquired, 
incites genomic instability and contributes to tumor initiation and progression.  While loss of 
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normal DSB/ICL repair capacity can be causally associated with cancer pathogenesis, the notion 
that dysfunction and hyperfunction of DNA repair pathways are both rational targets in anti-
neoplastic therapy is gaining momentum.  In this thesis, we have identified and mechanistically 
characterized a “druggable” interaction between BRCA1 and HSP90 that, when 
pharmacologically manipulated with a clinically-viable small molecule, can dramatically alter 
the ability of breast and ovarian cancer cells to recover after DSB/ICL induction.  This finding is 
of substantial clinical importance, as it is now appreciated that tumors with high expression of 
BRCA1 respond poorly to key classes of chemotherapeutic agents.  Our data indicate that HSP90 
inhibitors can destabilize BRCA1, and in effect, abolish BRCA1-dependent repair-mediated 
resistance.  We also provide compelling evidence that epigenetic inactivation of BRCA1 in 
aggressive TNBCs predicts poor response to a standard chemotherapeutic regimen used in breast 
cancer therapy, and that implementation of alternative agents which exploit the intrinsic 
vulnerability of BRCA1-deficient cells may lead to improved clinical outcomes.  Ultimately, this 
composition illuminates homologous recombination as a duplicitous process; in normal cells, HR 
is a custodian of genomic integrity and antagonizes malignant transformation, while in a cancer 
cell, this same pathway confers a sinister resistance that hampers the efficacy of therapy. 
 
 
 
 
 
 
 
181
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VI:  References 
 
  
182
 
(1999). Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl 
Cancer Inst 91, 1310-1316. 
Abbott, D.W., Thompson, M.E., Robinson-Benion, C., Tomlinson, G., Jensen, R.A., and Holt, 
J.T. (1999). BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells 
through enhancement of transcription-coupled DNA repair. J Biol Chem 274, 18808-18812. 
Adhikari, S., Choudhury, S., Mitra, P.S., Dubash, J.J., Sajankila, S.P., and Roy, R. (2008). 
Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem 8, 351-357. 
Alter, B.P., Greene, M.H., Velazquez, I., and Rosenberg, P.S. (2003). Cancer in Fanconi anemia. 
Blood 101, 2072. 
Ansquer, Y., Gautier, C., Fourquet, A., Asselain, B., and Stoppa-Lyonnet, D. (1998). Survival in 
early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 352, 541. 
Antoniou, A., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Loman, N., 
Olsson, H., Johannsson, O., Borg, A., et al. (2003). Average risks of breast and ovarian cancer 
associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family 
history: a combined analysis of 22 studies. Am J Hum Genet 72, 1117-1130. 
Antoniou, A.C., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Olsson, H., 
Johannsson, O., Borg, A., Pasini, B., et al. (2005). Breast and ovarian cancer risks to carriers of 
the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 
22 population based studies. J Med Genet 42, 602-603. 
Arlander, S.J., Eapen, A.K., Vroman, B.T., McDonald, R.J., Toft, D.O., and Karnitz, L.M. 
(2003). Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress. J Biol 
Chem 278, 52572-52577. 
Asakawa, H., Koizumi, H., Koike, A., Takahashi, M., Wu, W., Iwase, H., Fukuda, M., and Ohta, 
T. (2010). Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of 
DNA damage repair proteins. Breast Cancer Res 12, R17. 
Ashworth, A. (2008). Drug resistance caused by reversion mutation. Cancer Res 68, 10021-
10023. 
Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., 
Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., et al. (2010). Oral poly(ADP-ribose) polymerase 
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a 
proof-of-concept trial. Lancet 376, 245-251. 
Auerbach, A.D., and Wolman, S.R. (1976). Susceptibility of Fanconi's anaemia fibroblasts to 
chromosome damage by carcinogens. Nature 261, 494-496. 
Bagatell, R., Beliakoff, J., David, C.L., Marron, M.T., and Whitesell, L. (2005). Hsp90 inhibitors 
deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic 
anticancer activity with cisplatin. Int J Cancer 113, 179-188. 
183
 
Bagatell, R., Paine-Murrieta, G.D., Taylor, C.W., Pulcini, E.J., Akinaga, S., Benjamin, I.J., and 
Whitesell, L. (2000). Induction of a heat shock factor 1-dependent stress response alters the 
cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6, 3312-3318. 
Banath, J.P., Macphail, S.H., and Olive, P.L. (2004). Radiation sensitivity, H2AX 
phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell 
lines. Cancer Res 64, 7144-7149. 
Bau, D.T., Fu, Y.P., Chen, S.T., Cheng, T.C., Yu, J.C., Wu, P.E., and Shen, C.Y. (2004). Breast 
cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-
joining genes are affected by BRCA1. Cancer Res 64, 5013-5019. 
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., and Birnbaum, D. 
(2008). How basal are triple-negative breast cancers? Int J Cancer 123, 236-240. 
Berwick, M., and Vineis, P. (2000). Markers of DNA repair and susceptibility to cancer in 
humans: an epidemiologic review. J Natl Cancer Inst 92, 874-897. 
Bhattacharyya, A., Ear, U.S., Koller, B.H., Weichselbaum, R.R., and Bishop, D.K. (2000). The 
breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and 
survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275, 
23899-23903. 
Blackshear, P.E., Goldsworthy, S.M., Foley, J.F., McAllister, K.A., Bennett, L.M., Collins, N.K., 
Bunch, D.O., Brown, P., Wiseman, R.W., and Davis, B.J. (1998). Brca1 and Brca2 expression 
patterns in mitotic and meiotic cells of mice. Oncogene 16, 61-68. 
Blagg, B.S., and Kerr, T.D. (2006). Hsp90 inhibitors: small molecules that transform the Hsp90 
protein folding machinery into a catalyst for protein degradation. Med Res Rev 26, 310-338. 
Bolton, K.L., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S.J., Karlan, B.Y., 
Lambrechts, D., Despierre, E., Barrowdale, D., McGuffog, L., et al. (2012). Association between 
BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. 
JAMA 307, 382-390. 
Bordeleau, L., Panchal, S., and Goodwin, P. (2010). Prognosis of BRCA-associated breast 
cancer: a summary of evidence. Breast Cancer Res Treat 119, 13-24. 
Bridges, C.B. (1922). The origin of variation. Amer Nat 56, 51-63. 
Buller, R.E., Shahin, M.S., Geisler, J.P., Zogg, M., De Young, B.R., and Davis, C.S. (2002). 
Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8, 1196-1202. 
Burma, S., Chen, B.P., Murphy, M., Kurimasa, A., and Chen, D.J. (2001). ATM phosphorylates 
histone H2AX in response to DNA double-strand breaks. J Biol Chem 276, 42462-42467. 
184
 
Calza, S., Hall, P., Auer, G., Bjohle, J., Klaar, S., Kronenwett, U., Liu, E.T., Miller, L., Ploner, 
A., Smeds, J., et al. (2006). Intrinsic molecular signature of breast cancer in a population-based 
cohort of 412 patients. Breast Cancer Res 8, R34. 
Camphausen, K., and Tofilon, P.J. (2007). Inhibition of Hsp90: a multitarget approach to 
radiosensitization. Clin Cancer Res 13, 4326-4330. 
Cantu, M.G., Buda, A., Parma, G., Rossi, R., Floriani, I., Bonazzi, C., Dell'Anna, T., Torri, V., 
and Colombo, N. (2002). Randomized controlled trial of single-agent paclitaxel versus 
cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who 
responded to first-line platinum-based regimens. J Clin Oncol 20, 1232-1237. 
Carlson, R.W., and McCormick, B. (2005). Update: NCCN breast cancer Clinical Practice 
Guidelines. J Natl Compr Canc Netw 3 Suppl 1, S7-11. 
Cass, I., Baldwin, R.L., Varkey, T., Moslehi, R., Narod, S.A., and Karlan, B.Y. (2003). 
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97, 2187-2195. 
Catteau, A., Harris, W.H., Xu, C.F., and Solomon, E. (1999). Methylation of the BRCA1 
promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. 
Oncogene 18, 1957-1965. 
Chappuis, P.O., Goffin, J., Hamel, N., Wong, N., Paradis, A.J., Roberge, D., Brunet, J.S., Yee, 
C., Tonin, P., Boyd, J., et al. (2011). Good response to chemotherapy (CT) and hormonotherapy 
(HT) in patients with BRCA1-related breast cancer (BRCA1-BC) (abstract). Hum Genet Suppl 
69, 249. 
Chappuis, P.O., Goffin, J., Wong, N., Perret, C., Ghadirian, P., Tonin, P.N., and Foulkes, W.D. 
(2002). A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J 
Med Genet 39, 608-610. 
Chappuis, P.O., Kapusta, L., Begin, L.R., Wong, N., Brunet, J.S., Narod, S.A., Slingerland, J., 
and Foulkes, W.D. (2000). Germline BRCA1/2 mutations and p27(Kip1) protein levels 
independently predict outcome after breast cancer. J Clin Oncol 18, 4045-4052. 
Cheang, M.C., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S.K., Perou, C.M., and 
Nielsen, T.O. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic 
value than triple-negative phenotype. Clin Cancer Res 14, 1368-1376. 
Chen, L., Nievera, C.J., Lee, A.Y., and Wu, X. (2008). Cell cycle-dependent complex formation 
of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem 283, 7713-
7720. 
Chen, X., Arciero, C.A., and Godwin, A.K. (2006). BRCA1-associated complexes: new targets 
to overcome breast cancer radiation resistance. Expert Rev Anticancer Ther 6, 187-196. 
185
 
Chen, Y., Farmer, A.A., Chen, C.F., Jones, D.C., Chen, P.L., and Lee, W.H. (1996). BRCA1 is a 
220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent 
manner. Cancer Res 56, 3168-3172. 
Chen, Y., Zhou, J., Xu, Y., Li, Z., Wen, X., Yao, L., Xie, Y., and Deng, D. (2009). BRCA1 
promoter methylation associated with poor survival in Chinese patients with sporadic breast 
cancer. Cancer Sci 100, 1663-1667. 
Chiang, J.W., Karlan, B.Y., Cass, L., and Baldwin, R.L. (2006). BRCA1 promoter methylation 
predicts adverse ovarian cancer prognosis. Gynecol Oncol 101, 403-410. 
Chiba, N., and Parvin, J.D. (2002). The BRCA1 and BARD1 association with the RNA 
polymerase II holoenzyme. Cancer Res 62, 4222-4228. 
Chirnomas, D., Taniguchi, T., de la Vega, M., Vaidya, A.P., Vasserman, M., Hartman, A.R., 
Kennedy, R., Foster, R., Mahoney, J., Seiden, M.V., et al. (2006). Chemosensitization to 
cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5, 952-961. 
Chou, T.C., and Hayball, M.P. (1997). CalcuSyn for Windows: multiple-drug dose-effect 
analyzer and manual. (Cambridge (UK), Biosoft). 
Chou, T.C., and Talalay, P. (1983). Analysis of combined drug effects: a new look at a very old 
problem. Trends in Pharmacological Sciences 4, 450-454. 
Chou, T.C., and Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the 
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55. 
Choudhury, A.D., Xu, H., and Baer, R. (2004). Ubiquitination and proteasomal degradation of 
the BRCA1 tumor suppressor is regulated during cell cycle progression. J Biol Chem 279, 
33909-33918. 
Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., Godwin, J., Gray, R., 
Hicks, C., James, S., et al. (2005). Effects of radiotherapy and of differences in the extent of 
surgery for early breast cancer on local recurrence and 15-year survival: an overview of the 
randomised trials. Lancet 366, 2087-2106. 
Coene, E.D., Gadelha, C., White, N., Malhas, A., Thomas, B., Shaw, M., and Vaux, D.J. (2011). 
A novel role for BRCA1 in regulating breast cancer cell spreading and motility. J Cell Biol 192, 
497-512. 
Cortez, D., Wang, Y., Qin, J., and Elledge, S.J. (1999). Requirement of ATM-dependent 
phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286, 
1162-1166. 
Creagh, E.M., Sheehan, D., and Cotter, T.G. (2000). Heat shock proteins--modulators of 
apoptosis in tumour cells. Leukemia 14, 1161-1173. 
186
 
D'Andrea, A.D. (2010). Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J 
Med 362, 1909-1919. 
D'Andrea, A.D., and Grompe, M. (2003). The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 
3, 23-34. 
de Ronde, J.J., Hannemann, J., Halfwerk, H., Mulder, L., Straver, M.E., Vrancken Peeters, M.J., 
Wesseling, J., van de Vijver, M., Wessels, L.F., and Rodenhuis, S. (2010). Concordance of 
clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy 
response. Breast Cancer Res Treat 119, 119-126. 
Deans, A.J., and West, S.C. (2011). DNA interstrand crosslink repair and cancer. Nat Rev 
Cancer 11, 467-480. 
DelloRusso, C., Welcsh, P.L., Wang, W., Garcia, R.L., King, M.C., and Swisher, E.M. (2007). 
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to 
ionizing radiation. Mol Cancer Res 5, 35-45. 
Deng, C.X. (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response 
and cancer evolution. Nucleic Acids Res 34, 1416-1426. 
Dhillon, V.S., Shahid, M., and Husain, S.A. (2004). CpG methylation of the FHIT, FANCF, 
cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol 
Cancer 3, 33. 
Diehn, M., and Clarke, M.F. (2006). Cancer stem cells and radiotherapy: new insights into tumor 
radioresistance. J Natl Cancer Inst 98, 1755-1757. 
Dote, H., Burgan, W.E., Camphausen, K., and Tofilon, P.J. (2006). Inhibition of hsp90 
compromises the DNA damage response to radiation. Cancer Res 66, 9211-9220. 
Dungey, F.A., Caldecott, K.W., and Chalmers, A.J. (2009). Enhanced radiosensitization of 
human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of 
heat shock protein 90. Mol Cancer Ther 8, 2243-2254. 
Eastman, A. (1986). Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) 
with DNA. Biochemistry 25, 3912-3915. 
Edwards, S.L., Brough, R., Lord, C.J., Natrajan, R., Vatcheva, R., Levine, D.A., Boyd, J., Reis-
Filho, J.S., and Ashworth, A. (2008). Resistance to therapy caused by intragenic deletion in 
BRCA2. Nature 451, 1111-1115. 
El-Khamisy, S.F., Masutani, M., Suzuki, H., and Caldecott, K.W. (2003). A requirement for 
PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. 
Nucleic Acids Res 31, 5526-5533. 
187
 
Esteller, M., Silva, J.M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., 
Prat, J., Harkes, I.C., Repasky, E.A., et al. (2000). Promoter hypermethylation and BRCA1 
inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92, 564-569. 
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., 
Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in BRCA 
mutant cells as a therapeutic strategy. Nature 434, 917-921. 
Ferrer, M., de Winter, J.P., Mastenbroek, D.C., Curiel, D.T., Gerritsen, W.R., Giaccone, G., and 
Kruyt, F.A. (2004). Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with 
an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Ther 11, 539-546. 
Folias, A., Matkovic, M., Bruun, D., Reid, S., Hejna, J., Grompe, M., D'Andrea, A., and Moses, 
R. (2002). BRCA1 interacts directly with the Fanconi anemia protein FANCA. Hum Mol Genet 
11, 2591-2597. 
Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., 
Swaisland, H., Lau, A., O'Connor, M.J., et al. (2009). Inhibition of poly(ADP-ribose) 
polymerase in tumors from BRCA mutation carriers. N Engl J Med 361, 123-134. 
Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, 
J., Lubinski, J., Shanley, S., Messiou, C., et al. Poly(ADP)-Ribose Polymerase Inhibition: 
Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free 
Interval. J Clin Oncol. 
Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, 
J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010). Poly(ADP)-ribose polymerase inhibition: 
frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free 
interval. J Clin Oncol 28, 2512-2519. 
Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A., and Goldgar, D.E. (1994). Risks of cancer in 
BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692-695. 
Foulkes, W.D., Stefansson, I.M., Chappuis, P.O., Begin, L.R., Goffin, J.R., Wong, N., Trudel, 
M., and Akslen, L.A. (2003). Germline BRCA1 mutations and a basal epithelial phenotype in 
breast cancer. J Natl Cancer Inst 95, 1482-1485. 
Friedman, L.S., Ostermeyer, E.A., Szabo, C.I., Dowd, P., Lynch, E.D., Rowell, S.E., and King, 
M.C. (1994). Confirmation of BRCA1 by analysis of germline mutations linked to breast and 
ovarian cancer in ten families. Nat Genet 8, 399-404. 
Furuta, S., Jiang, X., Gu, B., Cheng, E., Chen, P.L., and Lee, W.H. (2005). Depletion of BRCA1 
impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad 
Sci U S A 102, 9176-9181. 
Gaffney, D.K., Brohet, R.M., Lewis, C.M., Holden, J.A., Buys, S.S., Neuhausen, S.L., Steele, L., 
Avizonis, V., Stewart, J.R., and Cannon-Albright, L.A. (1998). Response to radiation therapy 
188
 
and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 47, 
129-136. 
Gallagher, D.J., Konner, J.A., Bell-McGuinn, K.M., Bhatia, J., Sabbatini, P., Aghajanian, C.A., 
Offit, K., Barakat, R.R., Spriggs, D.R., and Kauff, N.D. (2011). Survival in epithelial ovarian 
cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. 
Ann Oncol 22, 1127-1132. 
Garcia, A.I., Buisson, M., Bertrand, P., Rimokh, R., Rouleau, E., Lopez, B.S., Lidereau, R., 
Mikaelian, I., and Mazoyer, S. (2011). Down-regulation of BRCA1 expression by miR-146a and 
miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 3, 279-290. 
Gebski, V., Lagleva, M., Keech, A., Simes, J., and Langlands, A.O. (2006). Survival effects of 
postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical 
perspective. J Natl Cancer Inst 98, 26-38. 
Georgakis, G.V., Li, Y., Rassidakis, G.Z., Medeiros, L.J., and Younes, A. (2006). The HSP90 
inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma 
irrespective of ALK expression. Exp Hematol 34, 1670-1679. 
Gluckman, E., Auerbach, A.D., Horowitz, M.M., Sobocinski, K.A., Ash, R.C., Bortin, M.M., 
Butturini, A., Camitta, B.M., Champlin, R.E., Friedrich, W., et al. (1995). Bone marrow 
transplantation for Fanconi anemia. Blood 86, 2856-2862. 
Gluckman, E., and Wagner, J.E. (2008). Hematopoietic stem cell transplantation in childhood 
inherited bone marrow failure syndrome. Bone Marrow Transplant 41, 127-132. 
Graeser, M., McCarthy, A., Lord, C.J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., 
Smith, I.E., Reis-Filho, J.S., et al. (2010). A marker of homologous recombination predicts 
pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin 
Cancer Res 16, 6159-6168. 
Gudas, J.M., Li, T., Nguyen, H., Jensen, D., Rauscher, F.J., 3rd, and Cowan, K.H. (1996). Cell 
cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 
7, 717-723. 
Guervilly, J.H., Mace-Aime, G., and Rosselli, F. (2008). Loss of CHK1 function impedes DNA 
damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi 
anemia. Hum Mol Genet 17, 679-689. 
Guha, M. (2011). PARP inhibitors stumble in breast cancer. Nat Biotechnol 29, 373-374. 
Hall, J.M., Lee, M.K., Newman, B., Morrow, J.E., Anderson, L.A., Huey, B., and King, M.C. 
(1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250, 1684-
1689. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
189
 
He, T.C., Zhou, S., da Costa, L.T., Yu, J., Kinzler, K.W., and Vogelstein, B. (1998). A simplified 
system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95, 2509-2514. 
Hennessy, B.T., Timms, K.M., Carey, M.S., Gutin, A., Meyer, L.A., Flake, D.D., 2nd, Abkevich, 
V., Potter, J., Pruss, D., Glenn, P., et al. (2010). Somatic mutations in BRCA1 and BRCA2 could 
expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in 
ovarian cancer. J Clin Oncol 28, 3570-3576. 
Holmberg, C.I., Hietakangas, V., Mikhailov, A., Rantanen, J.O., Kallio, M., Meinander, A., 
Hellman, J., Morrice, N., MacKintosh, C., Morimoto, R.I., et al. (2001). Phosphorylation of 
serine 230 promotes inducible transcriptional activity of heat shock factor 1. EMBO J 20, 3800-
3810. 
Huen, M.S., Sy, S.M., and Chen, J. BRCA1 and its toolbox for the maintenance of genome 
integrity. Nat Rev Mol Cell Biol 11, 138-148. 
Husain, A., He, G., Venkatraman, E.S., and Spriggs, D.R. (1998). BRCA1 up-regulation is 
associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58, 
1120-1123. 
Isakoff, S.J. (2010). Triple-negative breast cancer: role of specific chemotherapy agents. Cancer 
J 16, 53-61. 
Jasin, M. (2002). Homologous repair of DNA damage and tumorigenesis: the BRCA connection. 
Oncogene 21, 8981-8993. 
Johannsson, O.T., Ranstam, J., Borg, A., and Olsson, H. (1998). Survival of BRCA1 breast and 
ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16, 397-
404. 
Joukov, V., Chen, J., Fox, E.A., Green, J.B., and Livingston, D.M. (2001). Functional 
communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis 
development. Proc Natl Acad Sci U S A 98, 12078-12083. 
Jumppanen, M., Gruvberger-Saal, S., Kauraniemi, P., Tanner, M., Bendahl, P.O., Lundin, M., 
Krogh, M., Kataja, P., Borg, A., Ferno, M., et al. (2007). Basal-like phenotype is not associated 
with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9, R16. 
Kachhap, S.K., Vetale, S.P., Dange, P., and Ghosh, S.N. (2001). Reduced expression of the 
BRCA1 gene and increased chromosomal instability in MCF-7 cell line. Cell Biol Int 25, 547-
551. 
Khong, T., and Spencer, A. (2011). Targeting HSP 90 induces apoptosis and inhibits critical 
survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 10, 1909-1917. 
Kim, Y.J., Lee, S.A., Myung, S.C., Kim, W., and Lee, C.S. (2012). Radicicol, an inhibitor of 
Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by 
promoting activation of apoptosis-related proteins. Mol Cell Biochem 359, 33-43. 
190
 
Kim, Y.S., Alarcon, S.V., Lee, S., Lee, M.J., Giaccone, G., Neckers, L., and Trepel, J.B. (2009). 
Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9, 1479-1492. 
King, M.C., Marks, J.H., and Mandell, J.B. (2003). Breast and ovarian cancer risks due to 
inherited mutations in BRCA1 and BRCA2. Science 302, 643-646. 
Konstantinopoulos, P.A., Spentzos, D., Karlan, B.Y., Taniguchi, T., Fountzilas, E., Francoeur, 
N., Levine, D.A., and Cannistra, S.A. (2010). Gene expression profile of BRCAness that 
correlates with responsiveness to chemotherapy and with outcome in patients with epithelial 
ovarian cancer. J Clin Oncol 28, 3555-3561. 
Kutler, D.I., and Auerbach, A.D. (2004). Fanconi anemia in Ashkenazi Jews. Fam Cancer 3, 
241-248. 
Kutler, D.I., Singh, B., Satagopan, J., Batish, S.D., Berwick, M., Giampietro, P.F., Hanenberg, 
H., and Auerbach, A.D. (2003). A 20-year perspective on the International Fanconi Anemia 
Registry (IFAR). Blood 101, 1249-1256. 
Lacour, R.A., Westin, S.N., Meyer, L.A., Wingo, S.N., Schorge, J.O., Brooks, R., Mutch, D., 
Molina, A., Sutphen, R., Barnes, M., et al. (2011). Improved survival in non-Ashkenazi Jewish 
ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121, 358-363. 
Lafarge, S., Sylvain, V., Ferrara, M., and Bignon, Y.J. (2001). Inhibition of BRCA1 leads to 
increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK 
pathway. Oncogene 20, 6597-6606. 
Lakhani, S.R., Reis-Filho, J.S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., 
Bishop, T., Benitez, J., Rivas, C., Bignon, Y.J., et al. (2005). Prediction of BRCA1 status in 
patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11, 
5175-5180. 
Landais, I., Sobeck, A., Stone, S., LaChapelle, A., and Hoatlin, M.E. (2009). A novel cell-free 
screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer 124, 783-792. 
Lim, E., Vaillant, F., Wu, D., Forrest, N.C., Pal, B., Hart, A.H., Asselin-Labat, M.L., Gyorki, 
D.E., Ward, T., Partanen, A., et al. (2009). Aberrant luminal progenitors as the candidate target 
population for basal tumor development in BRCA1 mutation carriers. Nat Med 15, 907-913. 
Lim, S.L., Smith, P., Syed, N., Coens, C., Wong, H., van der Burg, M., Szlosarek, P., Crook, T., 
and Green, J.A. (2008). Promoter hypermethylation of FANCF and outcome in advanced ovarian 
cancer. Br J Cancer 98, 1452-1456. 
Lips, E.H., Laddach, N., Savola, S.P., Vollebergh, M.A., Oonk, A.M., Imholz, A.L., Wessels, 
L.F., Wesseling, J., Nederlof, P.M., and Rodenhuis, S. (2011). Quantitative copy number 
analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated 
breast cancer regions identifies BRCAness. Breast Cancer Res 13, R107. 
191
 
Liu, K.S., Liu, H., Qi, J.H., Liu, Q.Y., Liu, Z., Xia, M., Xing, G.W., Wang, S.X., and Wang, Y.F. 
(2011). SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of 
Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett. 
Liu, S., Ginestier, C., Charafe-Jauffret, E., Foco, H., Kleer, C.G., Merajver, S.D., Dontu, G., and 
Wicha, M.S. (2008). BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl 
Acad Sci U S A 105, 1680-1685. 
Liu, X., Shi, Y., Maag, D.X., Palma, J.P., Patterson, M.J., Ellis, P.A., Surber, B.W., Ready, D.B., 
Soni, N.B., Ladror, U.S., et al. (2012). Iniparib nonselectively modifies cysteine-containing 
proteins in tumor cells and is not a Bona Fide PARP inhibitor. Clin Cancer Res 18, 510-523. 
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408. 
Martin, S.A., McCarthy, A., Barber, L.J., Burgess, D.J., Parry, S., Lord, C.J., and Ashworth, A. 
(2009). Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells 
with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 1, 323-337. 
Masson, M., Niedergang, C., Schreiber, V., Muller, S., Menissier-de Murcia, J., and de Murcia, 
G. (1998). XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively 
regulates its activity following DNA damage. Mol Cell Biol 18, 3563-3571. 
Matros, E., Wang, Z.C., Lodeiro, G., Miron, A., Iglehart, J.D., and Richardson, A.L. (2005). 
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. 
Breast Cancer Res Treat 91, 179-186. 
McCabe, N., Turner, N.C., Lord, C.J., Kluzek, K., Bialkowska, A., Swift, S., Giavara, S., 
O'Connor, M.J., Tutt, A.N., Zdzienicka, M.Z., et al. (2006). Deficiency in the repair of DNA 
damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase 
inhibition. Cancer Res 66, 8109-8115. 
McCarthy, E.E., Celebi, J.T., Baer, R., and Ludwig, T. (2003). Loss of Bard1, the heterodimeric 
partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal 
instability. Mol Cell Biol 23, 5056-5063. 
McCollum, A.K., Lukasiewicz, K.B., Teneyck, C.J., Lingle, W.L., Toft, D.O., and Erlichman, C. 
(2008). Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 7, 
3256-3264. 
Merel, P., Prieur, A., Pfeiffer, P., and Delattre, O. (2002). Absence of major defects in non-
homologous DNA end joining in human breast cancer cell lines. Oncogene 21, 5654-5659. 
Miller, R.E., and Rustin, G.J. (2010). How to follow-up patients with epithelial ovarian cancer. 
Curr Opin Oncol 22, 498-502. 
192
 
Monk, B.J., and Coleman, R.L. (2009). Changing the paradigm in the treatment of platinum-
sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding 
antiangiogenesis compounds. Int J Gynecol Cancer 19 Suppl 2, S63-67. 
Morimoto, R.I. (1998). Regulation of the heat shock transcriptional response: cross talk between 
a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 12, 
3788-3796. 
Moskwa, P., Buffa, F.M., Pan, Y., Panchakshari, R., Gottipati, P., Muschel, R.J., Beech, J., 
Kulshrestha, R., Abdelmohsen, K., Weinstock, D.M., et al. (2011). miR-182-mediated 
downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41, 
210-220. 
Mullan, P.B., Quinn, J.E., Gilmore, P.M., McWilliams, S., Andrews, H., Gervin, C., McCabe, 
N., McKenna, S., White, P., Song, Y.H., et al. (2001). BRCA1 and GADD45 mediated G2/M 
cell cycle arrest in response to antimicrotubule agents. Oncogene 20, 6123-6131. 
Munster, P.N., Basso, A., Solit, D., Norton, L., and Rosen, N. (2001). Modulation of Hsp90 
function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an 
RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-
allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 
7: 2155-2158, 2001. Clin Cancer Res 7, 2228-2236. 
Nakanishi, K., Yang, Y.G., Pierce, A.J., Taniguchi, T., Digweed, M., D'Andrea, A.D., Wang, 
Z.Q., and Jasin, M. (2005). Human Fanconi anemia monoubiquitination pathway promotes 
homologous DNA repair. Proc Natl Acad Sci U S A 102, 1110-1115. 
Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., 
Livasy, C., Cowan, D., Dressler, L., et al. (2004). Immunohistochemical and clinical 
characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10, 
5367-5374. 
Noguchi, M., Yu, D., Hirayama, R., Ninomiya, Y., Sekine, E., Kubota, N., Ando, K., and 
Okayasu, R. (2006). Inhibition of homologous recombination repair in irradiated tumor cells 
pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys 
Res Commun 351, 658-663. 
Norquist, B., Wurz, K.A., Pennil, C.C., Garcia, R., Gross, J., Sakai, W., Karlan, B.Y., Taniguchi, 
T., and Swisher, E.M. (2011). Secondary Somatic Mutations Restoring BRCA1/2 Predict 
Chemotherapy Resistance in Hereditary Ovarian Carcinomas. J Clin Oncol. 
O'Shaughnessy, J., Osborne, C., Pippen, J.E., Yoffe, M., Patt, D., Rocha, C., Koo, I.C., Sherman, 
B.M., and Bradley, C. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast 
cancer. N Engl J Med 364, 205-214. 
Oda, T., Hayano, T., Miyaso, H., Takahashi, N., and Yamashita, T. (2007). Hsp90 regulates the 
Fanconi anemia DNA damage response pathway. Blood 109, 5016-5026. 
193
 
Oikawa, A., Tohda, H., Kanai, M., Miwa, M., and Sugimura, T. (1980). Inhibitors of 
poly(adenosine diphosphate ribose) polymerase induce sister chromatid exchanges. Biochem 
Biophys Res Commun 97, 1311-1316. 
Olive, P.L., and Banath, J.P. (2009). Kinetics of H2AX phosphorylation after exposure to 
cisplatin. Cytometry B Clin Cytom 76, 79-90. 
Phillips, T.M., McBride, W.H., and Pajonk, F. (2006). The response of CD24(-/low)/CD44+ 
breast cancer-initiating cells to radiation. J Natl Cancer Inst 98, 1777-1785. 
Potapova, A., Hoffman, A.M., Godwin, A.K., Al-Saleem, T., and Cairns, P. (2008). Promoter 
hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian 
cancer. Cancer Res 68, 998-1002. 
Powell, S.N., and Kachnic, L.A. (2003). Roles of BRCA1 and BRCA2 in homologous 
recombination, DNA replication fidelity and the cellular response to ionizing radiation. 
Oncogene 22, 5784-5791. 
Price, M., and Monteiro, A.N. (2010). Fine tuning chemotherapy to match BRCA1 status. 
Biochem Pharmacol 80, 647-653. 
Pujade-Lauraine, E., and Alexandre, J. (2011). Update of randomized trials in recurrent disease. 
Ann Oncol 22 Suppl 8, viii61-viii64. 
Quinn, J.E., James, C.R., Stewart, G.E., Mulligan, J.M., White, P., Chang, G.K., Mullan, P.B., 
Johnston, P.G., Wilson, R.H., and Harkin, D.P. (2007). BRCA1 mRNA expression levels predict 
for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13, 7413-7420. 
Quinn, J.E., Kennedy, R.D., Mullan, P.B., Gilmore, P.M., Carty, M., Johnston, P.G., and Harkin, 
D.P. (2003). BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. 
Cancer Res 63, 6221-6228. 
Rades, D., Veninga, T., Stalpers, L.J., Schulte, R., Hoskin, P.J., Poortmans, P., Schild, S.E., and 
Rudat, V. (2006). Prognostic factors predicting functional outcomes, recurrence-free survival, 
and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer 
patients. Int J Radiat Oncol Biol Phys 64, 182-188. 
Radosa, M.P., Hafner, N., Camara, O., Diebolder, H., Mothes, A., Winzer, H., Jansen, L., Durst, 
M., and Runnebaum, I.B. (2011). Loss of BRCA1 protein expression as indicator of the 
BRCAness phenotype is associated with favorable overall survival after complete resection of 
sporadic ovarian cancer. Int J Gynecol Cancer 21, 1399-1406. 
Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., 
Barfoot, R., Chagtai, T., et al. (2007). PALB2, which encodes a BRCA2-interacting protein, is a 
breast cancer susceptibility gene. Nat Genet 39, 165-167. 
194
 
Rajan, J.V., Wang, M., Marquis, S.T., and Chodosh, L.A. (1996). Brca2 is coordinately regulated 
with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad 
Sci U S A 93, 13078-13083. 
Rakha, E., Ellis, I., and Reis-Filho, J. (2008a). Are triple-negative and basal-like breast cancer 
synonymous? Clin Cancer Res 14, 618; author reply 618-619. 
Rakha, E., and Reis-Filho, J.S. (2009). Basal-like breast carcinoma: from expression profiling to 
routine practice. Arch Pathol Lab Med 133, 860-868. 
Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H., Robertson, J.F., and Ellis, I.O. (2007a). 
Prognostic markers in triple-negative breast cancer. Cancer 109, 25-32. 
Rakha, E.A., El-Sayed, M.E., Reis-Filho, J., and Ellis, I.O. (2009). Patho-biological aspects of 
basal-like breast cancer. Breast Cancer Res Treat 113, 411-422. 
Rakha, E.A., and Ellis, I.O. (2009). Triple-negative/basal-like breast cancer: review. Pathology 
41, 40-47. 
Rakha, E.A., Reis-Filho, J.S., and Ellis, I.O. (2008b). Basal-like breast cancer: a critical review. J 
Clin Oncol 26, 2568-2581. 
Rakha, E.A., Reis-Filho, J.S., and Ellis, I.O. (2008c). Impact of basal-like breast carcinoma 
determination for a more specific therapy. Pathobiology 75, 95-103. 
Rakha, E.A., Tan, D.S., Foulkes, W.D., Ellis, I.O., Tutt, A., Nielsen, T.O., and Reis-Filho, J.S. 
(2007b). Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer 
Res 9, 404; author reply 405. 
Ransburgh, D.J., Chiba, N., Ishioka, C., Toland, A.E., and Parvin, J.D. (2010). Identification of 
breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination. 
Cancer Res 70, 988-995. 
Recht, A., Edge, S.B., Solin, L.J., Robinson, D.S., Estabrook, A., Fine, R.E., Fleming, G.F., 
Formenti, S., Hudis, C., Kirshner, J.J., et al. (2001). Postmastectomy radiotherapy: clinical 
practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19, 1539-1569. 
Robson, M., Gilewski, T., Haas, B., Levin, D., Borgen, P., Rajan, P., Hirschaut, Y., Pressman, 
P., Rosen, P.P., Lesser, M.L., et al. (1998). BRCA-associated breast cancer in young women. J 
Clin Oncol 16, 1642-1649. 
Rodriguez-Pinilla, S.M., Sarrio, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., and 
Palacios, J. (2006). Prognostic significance of basal-like phenotype and fascin expression in 
node-negative invasive breast carcinomas. Clin Cancer Res 12, 1533-1539. 
Rogakou, E.P., Pilch, D.R., Orr, A.H., Ivanova, V.S., and Bonner, W.M. (1998). DNA double-
stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273, 5858-
5868. 
195
 
Rouzier, R., Perou, C.M., Symmans, W.F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, 
K.R., Stec, J., Ayers, M., Wagner, P., et al. (2005). Breast cancer molecular subtypes respond 
differently to preoperative chemotherapy. Clin Cancer Res 11, 5678-5685. 
Rubin, S.C., Benjamin, I., Behbakht, K., Takahashi, H., Morgan, M.A., LiVolsi, V.A., Berchuck, 
A., Muto, M.G., Garber, J.E., Weber, B.L., et al. (1996). Clinical and pathological features of 
ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335, 1413-1416. 
Rubinstein, W.S. (2004). Hereditary breast cancer in Jews. Fam Cancer 3, 249-257. 
Sakai, W., Swisher, E.M., Jacquemont, C., Chandramohan, K.V., Couch, F.J., Langdon, S.P., 
Wurz, K., Higgins, J., Villegas, E., and Taniguchi, T. (2009). Functional restoration of BRCA2 
protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69, 
6381-6386. 
Sakai, W., Swisher, E.M., Karlan, B.Y., Agarwal, M.K., Higgins, J., Friedman, C., Villegas, E., 
Jacquemont, C., Farrugia, D.J., Couch, F.J., et al. (2008). Secondary mutations as a mechanism 
of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120. 
Sanderson, R.J., and Lindahl, T. (2002). Down-regulation of DNA repair synthesis at DNA 
single-strand interruptions in poly(ADP-ribose) polymerase-1 deficient murine cell extracts. 
DNA Repair (Amst) 1, 547-558. 
Scardocci, A., Guidi, F., D'Alo, F., Gumiero, D., Fabiani, E., Diruscio, A., Martini, M., Larocca, 
L.M., Zollino, M., Hohaus, S., et al. (2006). Reduced BRCA1 expression due to promoter 
hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer 95, 1108-1113. 
Scata, K.A., and El-Deiry, W.S. (2007). p53, BRCA1 and breast Cancer chemoresistance. Adv 
Exp Med Biol 608, 70-86. 
Schwartz, P.E. (2008). What is the role of neoadjuvant chemotherapy in the management of 
ovarian cancer? Oncology (Williston Park) 22, 1118-1125; discussion 1130, 1132, 1134. 
Scully, R., Chen, J., Ochs, R.L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D.M. 
(1997). Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated 
by DNA damage. Cell 90, 425-435. 
Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, 
H., Ahmed, M., Spanova, K., et al. (2006). Truncating mutations in the Fanconi anemia J gene 
BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38, 1239-1241. 
Sharma, G., Mirza, S., Yang, Y.H., Parshad, R., Hazrah, P., Datta Gupta, S., and Ralhan, R. 
(2009). Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer 
patients. Cell Oncol 31, 487-500. 
Shrivastav, M., De Haro, L.P., and Nickoloff, J.A. (2008). Regulation of DNA double-strand 
break repair pathway choice. Cell Res 18, 134-147. 
196
 
Shukla, P.C., Singh, K.K., Quan, A., Al-Omran, M., Teoh, H., Lovren, F., Cao, L., Rovira, II, 
Pan, Y., Brezden-Masley, C., et al. (2011). BRCA1 is an essential regulator of heart function and 
survival following myocardial infarction. Nat Commun 2, 593. 
Silver, D.P., Richardson, A.L., Eklund, A.C., Wang, Z.C., Szallasi, Z., Li, Q., Juul, N., Leong, 
C.O., Calogrias, D., Buraimoh, A., et al. Efficacy of neoadjuvant Cisplatin in triple-negative 
breast cancer. J Clin Oncol 28, 1145-1153. 
Simbulan-Rosenthal, C.M., Haddad, B.R., Rosenthal, D.S., Weaver, Z., Coleman, A., Luo, R., 
Young, H.M., Wang, Z.Q., Ried, T., and Smulson, M.E. (1999). Chromosomal aberrations in 
PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-
ribose) polymerase cDNA. Proc Natl Acad Sci U S A 96, 13191-13196. 
Singh, K.K., Shukla, P.C., Quan, A., Desjardins, J.F., Lovren, F., Pan, Y., Garg, V., Gosal, S., 
Garg, A., Szmitko, P.E., et al. (2012). BRCA2 Protein Deficiency Exaggerates Doxorubicin-
induced Cardiomyocyte Apoptosis and Cardiac Failure. J Biol Chem 287, 6604-6614. 
Sinha, S., Singh, R.K., Alam, N., Roy, A., Roychoudhury, S., and Panda, C.K. (2008). 
Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: 
pathological significance in early- and late-onset breast carcinoma. Mol Cancer 7, 84. 
Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., 
van de Rijn, M., Jeffrey, S.S., et al. (2001). Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869-
10874. 
Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J.S., Nobel, A., Deng, S., Johnsen, H., 
Pesich, R., Geisler, S., et al. (2003). Repeated observation of breast tumor subtypes in 
independent gene expression data sets. Proc Natl Acad Sci U S A 100, 8418-8423. 
Spencer, D.M., Bilardi, R.A., Koch, T.H., Post, G.C., Nafie, J.W., Kimura, K., Cutts, S.M., and 
Phillips, D.R. (2008). DNA repair in response to anthracycline-DNA adducts: a role for both 
homologous recombination and nucleotide excision repair. Mutat Res 638, 110-121. 
Stoppa-Lyonnet, D., Ansquer, Y., Dreyfus, H., Gautier, C., Gauthier-Villars, M., Bourstyn, E., 
Clough, K.B., Magdelenat, H., Pouillart, P., Vincent-Salomon, A., et al. (2000). Familial 
invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18, 4053-
4059. 
Swisher, E.M., Gonzalez, R.M., Taniguchi, T., Garcia, R.L., Walsh, T., Goff, B.A., and Welcsh, 
P. (2009). Methylation and protein expression of DNA repair genes: association with 
chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 
8, 48. 
Swisher, E.M., Sakai, W., Karlan, B.Y., Wurz, K., Urban, N., and Taniguchi, T. (2008). 
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. 
Cancer Res 68, 2581-2586. 
197
 
Tan, D.S., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., 
Norman, A., Kaye, S.B., and Gore, M.E. (2008). "BRCAness" syndrome in ovarian cancer: a 
case-control study describing the clinical features and outcome of patients with epithelial ovarian 
cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26, 5530-5536. 
Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S.V., Mathew, C.G., Joenje, H., Mok, 
S.C., and D'Andrea, A.D. (2003). Disruption of the Fanconi anemia-BRCA pathway in cisplatin-
sensitive ovarian tumors. Nat Med 9, 568-574. 
Tassone, P., Blotta, S., Palmieri, C., Masciari, S., Quaresima, B., Montagna, M., D'Andrea, E., 
Eramo, O.P., Migale, L., Costanzo, F., et al. (2005). Differential sensitivity of BRCA1-mutated 
HCC1937 human breast cancer cells to microtubule-interfering agents. Int J Oncol 26, 1257-
1263. 
TCGA (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615. 
Teodoridis, J.M., Hall, J., Marsh, S., Kannall, H.D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., 
McLeod, H.L., Strathdee, G., et al. (2005). CpG island methylation of DNA damage response 
genes in advanced ovarian cancer. Cancer Res 65, 8961-8967. 
Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D., and Liu, L.F. (1984). Adriamycin-induced 
DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466-468. 
Thangaraju, M., Kaufmann, S.H., and Couch, F.J. (2000). BRCA1 facilitates stress-induced 
apoptosis in breast and ovarian cancer cell lines. J Biol Chem 275, 33487-33496. 
Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L., and Holt, J.T. (1995). Decreased 
expression of BRCA1 accelerates growth and is often present during sporadic breast cancer 
progression. Nat Genet 9, 444-450. 
Tibbetts, R.S., Cortez, D., Brumbaugh, K.M., Scully, R., Livingston, D., Elledge, S.J., and 
Abraham, R.T. (2000). Functional interactions between BRCA1 and the checkpoint kinase ATR 
during genotoxic stress. Genes Dev 14, 2989-3002. 
Tokunaga, E., Okada, S., Kitao, H., Shiotani, S., Saeki, H., Endo, K., Morita, M., Kakeji, Y., and 
Maehara, Y. (2009). Low incidence of methylation of the promoter region of the FANCF gene in 
Japanese primary breast cancer. Breast Cancer. 
Turner, N., Tutt, A., and Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. 
Nat Rev Cancer 4, 814-819. 
Turner, N.C., and Reis-Filho, J.S. (2006). Basal-like breast cancer and the BRCA1 phenotype. 
Oncogene 25, 5846-5853. 
Turner, N.C., Reis-Filho, J.S., Russell, A.M., Springall, R.J., Ryder, K., Steele, D., Savage, K., 
Gillett, C.E., Schmitt, F.C., Ashworth, A., et al. (2007). BRCA1 dysfunction in sporadic basal-
like breast cancer. Oncogene 26, 2126-2132. 
198
 
Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, 
M., Arun, B., Loman, N., Schmutzler, R.K., et al. (2010). Oral poly(ADP-ribose) polymerase 
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a 
proof-of-concept trial. Lancet 376, 235-244. 
van der Groep, P., Hoelzel, M., Buerger, H., Joenje, H., de Winter, J.P., and van Diest, P.J. 
(2008). Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. Breast 
Cancer Res Treat 107, 41-47. 
van der Linden, Y.M., Dijkstra, S.P., Vonk, E.J., Marijnen, C.A., and Leer, J.W. (2005). 
Prediction of survival in patients with metastases in the spinal column: results based on a 
randomized trial of radiotherapy. Cancer 103, 320-328. 
Vaughn, J.P., Davis, P.L., Jarboe, M.D., Huper, G., Evans, A.C., Wiseman, R.W., Berchuck, A., 
Iglehart, J.D., Futreal, P.A., and Marks, J.R. (1996). BRCA1 expression is induced before DNA 
synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 7, 711-715. 
Vencken, P.M., Kriege, M., Hoogwerf, D., Beugelink, S., van der Burg, M.E., Hooning, M.J., 
Berns, E.M., Jager, A., Collee, M., Burger, C.W., et al. (2011). Chemosensitivity and outcome of 
BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared 
with sporadic ovarian cancer patients. Ann Oncol 22, 1346-1352. 
Verhoog, L.C., Brekelmans, C.T., Seynaeve, C., van den Bosch, L.M., Dahmen, G., van Geel, 
A.N., Tilanus-Linthorst, M.M., Bartels, C.C., Wagner, A., van den Ouweland, A., et al. (1998). 
Survival and tumour characteristics of breast-cancer patients with germline mutations of 
BRCA1. Lancet 351, 316-321. 
Vollebergh, M.A., Lips, E.H., Nederlof, P.M., Wessels, L.F., Schmidt, M.K., van Beers, E.H., 
Cornelissen, S., Holtkamp, M., Froklage, F.E., de Vries, E.G., et al. (2011). An aCGH classifier 
derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based 
chemotherapy in HER2-negative breast cancer patients. Ann Oncol 22, 1561-1570. 
Wadasadawala, T., Gupta, S., Bagul, V., and Patil, N. (2007). Brain metastases from breast 
cancer: management approach. J Cancer Res Ther 3, 157-165. 
Wagner, J.M., and Kaufmann, S.H. (2010). Prospects for the Use of ATR Inhibitors to Treat 
Cancer. Pharmaceuticals 3, 1311-1334. 
Wakabayashi, M.T., Lin, P.S., and Hakim, A.A. (2008). The role of cytoreductive/debulking 
surgery in ovarian cancer. J Natl Compr Canc Netw 6, 803-810; quiz 811. 
Wang, W. (2007). Emergence of a DNA-damage response network consisting of Fanconi 
anaemia and BRCA proteins. Nat Rev Genet 8, 735-748. 
Wang, Y., Yu, J., and Zhan, Q. (2008). BRCA1 regulates caveolin-1 expression and inhibits cell 
invasiveness. Biochem Biophys Res Commun 370, 201-206. 
199
 
Wang, Y.Q., Zhang, J.R., Li, S.D., He, Y.Y., Yang, Y.X., Liu, X.L., and Wan, X.P. (2010). 
Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human 
ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway. Cancer Sci 
101, 1618-1623. 
Wang, Z., Li, M., Lu, S., Zhang, Y., and Wang, H. (2006). Promoter hypermethylation of 
FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi 
anemia-BRCA pathway. Cancer Biol Ther 5, 256-260. 
Wang, Z.Q., Stingl, L., Morrison, C., Jantsch, M., Los, M., Schulze-Osthoff, K., and Wagner, 
E.F. (1997). PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 
11, 2347-2358. 
Weberpals, J., Garbuio, K., O'Brien, A., Clark-Knowles, K., Doucette, S., Antoniouk, O., Goss, 
G., and Dimitroulakos, J. (2009). The DNA repair proteins BRCA1 and ERCC1 as predictive 
markers in sporadic ovarian cancer. Int J Cancer 124, 806-815. 
Wei, L., Lan, L., Hong, Z., Yasui, A., Ishioka, C., and Chiba, N. (2008a). Rapid recruitment of 
BRCA1 to DNA double-strand breaks is dependent on its association with Ku80. Mol Cell Biol 
28, 7380-7393. 
Wei, M., Grushko, T.A., Dignam, J., Hagos, F., Nanda, R., Sveen, L., Xu, J., Fackenthal, J., 
Tretiakova, M., Das, S., et al. (2005). BRCA1 promoter methylation in sporadic breast cancer is 
associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65, 
10692-10699. 
Wei, M., Xu, J., Dignam, J., Nanda, R., Sveen, L., Fackenthal, J., Grushko, T.A., and Olopade, 
O.I. (2008b). Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in 
distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 111, 113-120. 
Weigelt, B., Baehner, F.L., and Reis-Filho, J.S. (2010). The contribution of gene expression 
profiling to breast cancer classification, prognostication and prediction: a retrospective of the last 
decade. J Pathol 220, 263-280. 
Whitesell, L., and Lindquist, S.L. (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer 
5, 761-772. 
Willers, H., Kachnic, L.A., Luo, C.M., Li, L., Purschke, M., Borgmann, K., Held, K.D., and 
Powell, S.N. (2008). Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol 
2008, 821529. 
Willers, H., Taghian, A.G., Luo, C.M., Treszezamsky, A., Sgroi, D.C., and Powell, S.N. (2009). 
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast 
cancer biopsies. Mol Cancer Res 7, 1304-1309. 
Woodhouse, B.C., Dianova, II, Parsons, J.L., and Dianov, G.L. (2008). Poly(ADP-ribose) 
polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand 
breaks. DNA Repair (Amst) 7, 932-940. 
200
 
Woodward, W.A., Chen, M.S., Behbod, F., Alfaro, M.P., Buchholz, T.A., and Rosen, J.M. 
(2007). WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. 
Proc Natl Acad Sci U S A 104, 618-623. 
Wynne, P., Newton, C., Ledermann, J.A., Olaitan, A., Mould, T.A., and Hartley, J.A. (2007). 
Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following 
treatment with platinum-based chemotherapy. Br J Cancer 97, 927-933. 
Xian Ma, Y., Fan, S., Xiong, J., Yuan, R.Q., Meng, Q., Gao, M., Goldberg, I.D., Fuqua, S.A., 
Pestell, R.G., and Rosen, E.M. (2003). Role of BRCA1 in heat shock response. Oncogene 22, 
10-27. 
Xu, X., Gammon, M.D., Zhang, Y., Bestor, T.H., Zeisel, S.H., Wetmur, J.G., Wallenstein, S., 
Bradshaw, P.T., Garbowski, G., Teitelbaum, S.L., et al. (2009). BRCA1 promoter methylation is 
associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 
115, 397-404. 
Xu, X., Gammon, M.D., Zhang, Y., Cho, Y.H., Wetmur, J.G., Bradshaw, P.T., Garbowski, G., 
Hibshoosh, H., Teitelbaum, S.L., Neugut, A.I., et al. (2010). Gene promoter methylation is 
associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 
121, 685-692. 
Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L., Wynshaw-
Boris, A., and Deng, C.X. (1999). Conditional mutation of Brca1 in mammary epithelial cells 
results in blunted ductal morphogenesis and tumour formation. Nat Genet 22, 37-43. 
Yamane, K., Schupp, J.E., and Kinsella, T.J. (2007). BRCA1 activates a G2-M cell cycle 
checkpoint following 6-thioguanine-induced DNA mismatch damage. Cancer Res 67, 6286-
6292. 
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A.K., and Zhang, W. (2011). 
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene 
mutator phenotype in patients with ovarian cancer. JAMA 306, 1557-1565. 
Yang, Q., Sakurai, T., Mori, I., Yoshimura, G., Nakamura, M., Nakamura, Y., Suzuma, T., 
Tamaki, T., Umemura, T., and Kakudo, K. (2001). Prognostic significance of BRCA1 expression 
in Japanese sporadic breast carcinomas. Cancer 92, 54-60. 
Yao, Q., Weigel, B., and Kersey, J. (2007). Synergism between etoposide and 17-AAG in 
leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer 
Res 13, 1591-1600. 
Yarden, R.I., Pardo-Reoyo, S., Sgagias, M., Cowan, K.H., and Brody, L.C. (2002). BRCA1 
regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30, 
285-289. 
201
 
Yasmeen, A., Liu, W., Dekhil, H., Kassab, A., Aloyz, R., Foulkes, W.D., and Al Moustafa, A.E. 
(2008). BRCA1 mutations contribute to cell motility and invasion by affecting its main 
regulators. Cell Cycle 7, 3781-3783. 
Yin, H., and Glass, J. (2011). The phenotypic radiation resistance of CD44+/CD24(-or low) 
breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One 6, 
e24080. 
Yu, X., Wu, L.C., Bowcock, A.M., Aronheim, A., and Baer, R. (1998). The C-terminal (BRCT) 
domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of 
transcriptional repression. J Biol Chem 273, 25388-25392. 
Zajac, M., Moneo, M.V., Carnero, A., Benitez, J., and Martinez-Delgado, B. (2008). Mitotic 
catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast 
cancer cell lines. Mol Cancer Ther 7, 2358-2366. 
Zhang, F., Fan, Q., Ren, K., and Andreassen, P.R. (2009). PALB2 functionally connects the 
breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res 7, 1110-1118. 
Zhong, Q., Chen, C.F., Li, S., Chen, Y., Wang, C.C., Xiao, J., Chen, P.L., Sharp, Z.D., and Lee, 
W.H. (1999). Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA 
damage response. Science 285, 747-750. 
Zhuang, J., Zhang, J., Willers, H., Wang, H., Chung, J.H., van Gent, D.C., Hallahan, D.E., 
Powell, S.N., and Xia, F. (2006). Checkpoint kinase 2-mediated phosphorylation of BRCA1 
regulates the fidelity of nonhomologous end-joining. Cancer Res 66, 1401-1408. 
Zou, J., Guo, Y., Guettouche, T., Smith, D.F., and Voellmy, R. (1998). Repression of heat shock 
transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive 
complex with HSF1. Cell 94, 471-480. 
 
 
  
202
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A:  Drug Synergy Calculations 
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The following has been adapted from the manual for CalcuSyn (Chou and Hayball, 1997). 
For the median-effect equation: 
    [
  
    
]
 
 
 
          [Eq. 1] 
    
where   is the dose of drug,    is the median-effect dose signifying potency,    is the fraction 
of cells affected by dose , and  is an exponent signifying the sigmoidicity of the dose-effect 
curve.     can be readily determined by calculating the x-intercept of the median-effect plot, 
according to the graphical representation of: 
        [ ]    versus           [
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          [Eq. 2] 
The slope of the median-effect plot will yield  , and     if the dose-effect curve is 
hyperbolic,     for sigmoidal curves, and    for negative-sigmoidal curves. 
Equation 1 may be linearized to give: 
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          [Eq. 3] 
Substituting: 
       [ ] 
          [Eq. 4] 
        [
  
    
] 
          [Eq. 5] 
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            [  ] 
          [Eq. 6] 
Equation 3 can be represented by the straight-line equation: 
            
          [Eq. 7] 
Linear regression of Equation 4 produces non-independent parameters      (the y-intercept) and 
  (the slope), and the statistical relationship between these two parameters is the correlation 
coefficient     : 
            [ ]̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ [
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          [Eq. 8] 
By rearranging Equation 6,      [  ] can be derived as: 
     [  ]     
    
 
 
          [Eq. 9] 
Assuming the errors of      and  are normally distributed, the parameter      [  ] must also 
be normally distributed according to: 
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          [Eq. 10] 
Similarly, the error in   can be can be derived by a similar treatment.  Rearranging Equation 3 to 
yield: 
     [ ]  
 
 
[     [
  
    
]      ] 
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          [Eq. 11] 
lends to an estimation in the error of      [ ] of: 
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          [Eq. 12] 
To evaluate the combinatorial effect of two drugs, the combination index    for a given effect 
can be represented by: 
       
  
   
  
 
  
   
  
  
  
   
  
   
    
 
          [Eq. 13] 
where     for a mutually non-exclusive case and     for a mutually exclusive case, and    
refers to the dose of drug A alone required to manifest a given effect and   
   
 refers to the dose 
of drug A in combination with drug B which gives an equal effect. 
 
If the ratio of quantities of each drug is constant across a range of doses, then: 
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          [Eq. 14] 
Thus, for constant ratio experimental parameters, Equation 13 can be expressed as: 
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          [Eq. 15] 
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Algebraic estimation of the uncertainty in    makes the assumption that the uncertainty is 
normally distributed.  Since the doses of drugs A and B are logarithmically distributed, this 
method is not ideal, but such estimation appears to be a fairly valid assumption and avoids the 
tedious process of calculating the uncertainty in    using iterative random sampling.  The 
standard deviation of the dose of drug is estimated as: 
  [ ]  
(  (         [      ])     (         [      ]))
 
 
          [Eq. 16] 
and thus the approximated error in    for mutually exclusive cases (i.e.,    ) becomes: 
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          [Eq. 17] 
When     , combinatorial drug effects are additive, and the manifested activity of one drug is 
independent of the activity of the other drug in the combination.  For      , the net effect of 
the two drugs in combination is greater than the sum of the expected effect of both drugs alone at 
their equivalent concentrations, thus inferring a synergistic relationship between drugs A and B.  
When     , the combination of drugs A and B produces an effect that is less than the sum of 
the expected effect of both drugs alone at their equivalent concentrations, suggesting antagonism 
between drugs A and B.  The   is a widely accepted quantifier of combinatorial drug 
interactions (Chou and Talalay, 1983, 1984). 
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